ID	Upstream event	Relationship type	Downstream event
5	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"	leads to	"Reduction, Plasma 17beta-estradiol concentrations"
9	"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"	leads to	"Decreased, Mitochondrial fatty acid beta-oxidation"
11	"Inhibition, Acetylcholinesterase (AchE)"	leads to	"Accumulation, Acetylcholine in synapses"
16	"Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways"	leads to	"Altered, Cardiovascular development/function"
17	"Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways"	leads to	"Up Regulation, CYP1A1"
18	"Activation, AHR"	leads to	"Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways"
19	"Activation, AHR"	leads to	"Up Regulation, CYP1A1"
23	"Alkylation, DNA"	leads to	"Increase, Heritable mutations in offspring"
24	"Alkylation, DNA"	leads to	"N/A, Insufficient or incorrect DNA repair"
25	"Alkylation, DNA"	leads to	"Increase, Mutations"
31	"Agonism, Androgen receptor"	leads to	"Reduction, Gonadotropins, circulating concentrations"
32	"Agonism, Androgen receptor"	leads to	"Reduction, Testosterone synthesis by ovarian theca cells"
33	"N/A, Androgen receptor, Antagonism"	leads to	"Decreased, Transcription of genes by AR"
35	"N/A, Androgen receptor, Antagonism"	leads to	"Alteration, Wnt pathway"
36	"Reduction, Angiogenic sprouting"	leads to	"Impairment, Endothelial network"
43	"Decrease, Aromatase (Cyp19a1)"	leads to	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
45	"Inhibition, Aromatase"	leads to	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
51	"Induction, Ataxia, paralysis, or hyperactivity"	leads to	"Decrease, Population trajectory"
53	"Up Regulation, Biliary excretion"	leads to	"Decrease, Serum thyroxine (T4)"
59	"Reduction, Ca and HCO3 transport to shell gland"	leads to	"Reduction, Eggshell thickness"
60	"Increase, Ca++ (intracellular)"	leads to	"Disruption, Mitochondrial electron transport chain"
61	"Inhibition, Ca++ ATPase"	leads to	"Increase, Ca++ (intracellular)"
62	"Decreased, Calcium influx"	leads to	"Impairment, Learning and memory"
66	"Up Regulation, CD36"	leads to	"Increase, FA Influx"
67	"N/A, Cell injury/death"	leads to	"Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)"
68	"N/A, Cell injury/death"	leads to	"Activation, Stellate cells"
69	"Proliferation, Cell proliferation in the absence of cytotoxicity"	leads to	"Hyperplasia, Hyperplasia"
70	"Induction, Chitin degradation and resorption"	leads to	"Induction, Pre-mature molting"
73	"Induction, Chitin synthesis"	leads to	"Induction, Pre-mature molting"
77	"Activation, ChREBP"	leads to	"Synthesis, De Novo FA"
82	"Accumulation, Collagen"	leads to	"N/A, Liver fibrosis"
85	"Activation, Constitutive androstane receptor, NR1l3"	leads to	"Induction, Upregulation of glucuronyltransferase activity"
88	"N/A, Covalent binding to protein, possibly lysine residue"	leads to	"Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways"
93	"Production, Critical Metabolites (CGA 330050 and CGA 265307)"	leads to	"Induction, Liver “Dysfunctional” Changes by CGA 330050"
94	"Reduction, Cumulative fecundity and spawning"	leads to	"Decrease, Population trajectory"
95	"Inhibition, Cyclooxygenase activity"	leads to	"Reduction, Prostaglandin E2 concentration"
96	"Up Regulation, CYP1A1"	leads to	"Increase, Oxidative Stress"
104	"Up Regulation, CYP1B1"	leads to	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
108	"Release, Cytokine"	leads to	"Increase, Inflammation"
110	"Synthesis, De Novo FA"	leads to	"Accumulation, Triglyceride"
116	"Activation, EcR"	leads to	"Induction, Chitin degradation and resorption"
118	"Activation, EcR"	leads to	"Induction, Chitin synthesis"
123	"Reduction, Eggshell thickness"	leads to	"N/A, Reproductive failure"
125	"Impairment, Endothelial network"	leads to	"Insufficiency, Vascular"
126	"Agonism, Estrogen receptor"	leads to	"Altered, Reproductive behaviour"
127	"Agonism, Estrogen receptor"	leads to	"Impaired development of, Reproductive organs"
128	"Agonism, Estrogen receptor"	leads to	"Increase, Vitellogenin synthesis in liver"
129	"Antagonism, Estrogen receptor"	leads to	"Reduction, Vitellogenin synthesis in liver"
132	"Increase, FA Influx"	leads to	"Accumulation, Triglyceride"
133	"Activation, FAS"	leads to	"Synthesis, De Novo FA"
134	"Accumulation, Fatty acid"	leads to	"Undefined, Liver Steatosis"
135	"Reduction, Fecundity"	leads to	"Decline, Population"
136	"N/A, Gap"	leads to	"Reduction, Ca and HCO3 transport to shell gland"
143	"Reduction, Gonadotropins, circulating concentrations"	leads to	"Reduction, Testosterone synthesis by ovarian theca cells"
144	"Depletion, GSH"	leads to	"N/A, Oxidative stress"
146	"Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)"	leads to	"Increase, Oxidative Stress"
147	"Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)"	leads to	"Up Regulation, TGFbeta1 expression"
148	"Increase, Hepatic transport of parent T4"	leads to	"Up Regulation, Biliary excretion"
149	"Up Regulation, Hepatic transporter gene expression"	leads to	"Increase, Hepatic transport of parent T4"
154	"Decreased, HSD17B10 expression"	leads to	"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"
158	"Hyperplasia, Hyperplasia"	leads to	"Promotion, Hepatocelluar carcinoma"
159	"Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307"	leads to	"Induction, Sustained Hepatotoxicity"
164	"N/A, Insufficient or incorrect DNA repair"	leads to	"Increase, Mutations"
168	"N/A, Interferences with SH-/selen-proteins"	leads to	"Depletion, GSH"
169	"Increase, Liver and splenic hemosiderosis"	leads to	"N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"
170	"Induction, Liver “Dysfunctional” Changes by CGA 330050"	leads to	"Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307"
172	"Activation, Long term AHR receptor driven direct and indirect gene expression changes"	leads to	"N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"
173	"Activation, LXR"	leads to	"Up Regulation, CD36"
174	"Activation, LXR"	leads to	"Activation, ChREBP"
175	"Activation, LXR"	leads to	"Activation, FAS"
176	"Activation, LXR"	leads to	"Activation, SCD-1"
177	"Activation, LXR"	leads to	"Activation, SREBP-1c"
182	"N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"	leads to	"N/A, Cyanosis occurs"
188	"Disruption, Mitochondrial electron transport chain"	leads to	"Decreased, ATP production"
189	"Disruption, Mitochondrial electron transport chain"	leads to	"Increased, ROS production"
190	"Decreased, Mitochondrial fatty acid beta-oxidation"	leads to	"Accumulation, Fatty acid"
194	"Abnormal, Morphogenesis"	leads to	"Decreased, Fetal birth weight"
195	"Abnormal, Morphogenesis"	leads to	"Increased, Functional deficits"
196	"Abnormal, Morphogenesis"	leads to	"Increased, Lethality"
197	"Abnormal, Morphogenesis"	leads to	"Increased, Structural malformations"
198	"Increase, Mortality"	leads to	"Reduction, Fecundity"
199	"Increase, Mortality"	leads to	"Decline, Population"
200	"Increased, Mortality"	leads to	"Decline, Population"
202	"Increase, Mutations"	leads to	"Increase, Heritable mutations in offspring"
203	"Altered, Neuroanatomy"	leads to	"Altered, Neurophysiology"
207	"N/A, Neurodegeneration"	leads to	"N/A, Neuroinflammation"
208	"N/A, Neuroinflammation"	leads to	"N/A, Neurodegeneration"
210	"N/A, Neuronal dysfunction"	leads to	"N/A, Neuroinflammation"
212	"Decreased, Nitric Oxide"	leads to	"Decreased, Long-term potentiation (LTP)"
213	"Inhibition, NMDARs"	leads to	"Decreased, Calcium influx"
214	"Inhibition, NMDARs"	leads to	"Impairment, Learning and memory"
215	"Inhibition, NMDARs"	leads to	"N/A, Neuronal dysfunction"
228	"Binding of antagonist, NMDA receptors"	leads to	"Impairment, Learning and memory"
229	"Binding of antagonist, NMDA receptors"	leads to	"Inhibition, NMDARs"
235	"Increase, Oxidative Stress"	leads to	"N/A, Embryotoxicity"
236	"Increase, Oxidative Stress"	leads to	"Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)"
238	"Increase, Oxidative Stress"	leads to	"Increase, Pericardial edema"
239	"N/A, Oxidative stress"	leads to	"N/A, Neuronal dysfunction"
240	"Propagation, Oxidative stress"	leads to	"Down Regulation, Gulcose-6-phosphate dehydrogenase"
241	"Propagation, Oxidative stress"	leads to	"Damaging, Red blood cells; hemolysis"
242	"N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin"	leads to	"Altered regulation, Alpha hemoglobin"
243	"N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin"	leads to	"Formation, Formation of hemoglobin adducts"
244	"N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin"	leads to	"Propagation, Oxidative stress"
245	"N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin"	leads to	"Damaging, Red blood cells; hemolysis"
248	"Bile accumulation, Pathological condition"	leads to	"Activation of specific nuclear receptors, Transcriptional change"
252	"Reduction, Plasma 17beta-estradiol concentrations"	leads to	"Reduction, Vitellogenin synthesis in liver"
253	"Reduction, Plasma 17beta-estradiol concentrations"	leads to	"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"
254	"Increase, Plasma vitellogenin concentrations"	leads to	"Increase, Renal pathology due to VTG deposition"
255	"Reduction, Plasma vitellogenin concentrations"	leads to	"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"
256	"Activation, PPAR?"	leads to	"Decrease, Aromatase (Cyp19a1)"
257	"Decreased, PPAR-alpha activation"	leads to	"Decreased, HSD17B10 expression"
259	"Decreased, PPAR-beta activation"	leads to	"Decreased, HSD17B10 expression"
260	"Decreased, PPAR-gamma activation"	leads to	"Decreased, HSD17B10 expression"
261	"Induction, Pre-mature molting"	leads to	"Reduction, Fecundity"
262	"Induction, Pre-mature molting"	leads to	"Increase, Mortality"
263	"Induction, Pre-mature molting"	leads to	"Increased, Mortality"
264	"Activation, Pregnane-X receptor, NR1l2"	leads to	"Up Regulation, Hepatic transporter gene expression"
265	"Activation, Pregnane-X receptor, NR1l2"	leads to	"Induction, Upregulation of glucuronyltransferase activity"
266	"Feminisation or incomplete development, Primary and accessory male sex organs"	leads to	"N/A, Impairment of reproductive capacity"
268	"Reduction, Prostaglandin E2 concentration"	leads to	"N/A, Gap"
269	"Alkylation, Protein"	leads to	"N/A, Cell injury/death"
271	"Alkylation, Protein"	leads to	"Increase, Oxidative Stress"
272	"Increase, RBC congestion in liver"	leads to	"N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"
276	"Production, Reactive oxygen species"	leads to	"Increase, Oxidative Stress"
277	"Damaging, Red blood cells; hemolysis"	leads to	"Increase, Liver and splenic hemosiderosis"
278	"Damaging, Red blood cells; hemolysis"	leads to	"N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"
279	"Damaging, Red blood cells; hemolysis"	leads to	"Increase, RBC congestion in liver"
280	"Increase, Renal pathology due to VTG deposition"	leads to	"Altered, Larval development"
282	"Increased, ROS production"	leads to	"Decreased, Nitric Oxide"
283	"Increased, ROS production"	leads to	"Increased, Oxidative damage"
284	"Activation, SCD-1"	leads to	"Synthesis, De Novo FA"
285	"Decrease, Serum thyroxine (T4)"	leads to	"Decrease, Tissue thyroid hormone concentration"
287	"Binding, SH-/selen-proteins"	leads to	"N/A, Interferences with SH-/selen-proteins"
294	"Activation, SREBP-1c"	leads to	"Synthesis, De Novo FA"
295	"Activation, Stellate cells"	leads to	"Accumulation, Collagen"
296	"Increased, Structural malformations"	leads to	"Increased, Lethality"
297	"Damage, Structure of the cochlea"	leads to	"Loss, Cochlear function"
298	"Induction, Sustained Cell Proliferation"	leads to	"Formation, Liver tumor"
299	"Induction, Sustained Hepatotoxicity"	leads to	"Induction, Sustained Cell Proliferation"
301	"Activation/Proliferation, T-cells"	leads to	"N/A, Allergic contact dermatitis on challenge"
302	"Reduction, Testosterone synthesis by ovarian theca cells"	leads to	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
303	"Up Regulation, TGFbeta1 expression"	leads to	"Accumulation, Collagen"
304	"Up Regulation, TGFbeta1 expression"	leads to	"Activation, Stellate cells"
305	"Thyroid hormone synthesis, Decreased"	leads to	"Thyroxine (T4) in serum, Decreased"
309	"Thyroperoxidase, Inhibition"	leads to	"Thyroid hormone synthesis, Decreased"
312	"Thyroxine (T4) in serum, Decreased"	leads to	"Thyroxine (T4) in neuronal tissue, Decreased"
313	"Decrease, Tissue thyroid hormone concentration"	leads to	"Decrease, TR-regulated cochlear proteins"
314	"Decrease, TR-regulated cochlear proteins"	leads to	"Damage, Structure of the cochlea"
315	"Reduction, Vitellogenin synthesis in liver"	leads to	"Reduction, Plasma vitellogenin concentrations"
316	"Decreased, Transcription of genes by AR"	leads to	"Feminisation or incomplete development, Primary and accessory male sex organs"
317	"Decreased, Transcription of genes by AR"	leads to	"Alteration, Wnt pathway"
319	"Activation of specific nuclear receptors, Transcriptional change"	leads to	"Cholestasis, Pathology"
321	"Accumulation, Triglyceride"	leads to	"Damaging, Mitochondria"
324	"N/A, Unknown"	leads to	"Proliferation, Cell proliferation in the absence of cytotoxicity"
327	"Induction, Upregulation of glucuronyltransferase activity"	leads to	"Up Regulation, Biliary excretion"
329	"Insufficiency, Vascular"	leads to	"Abnormal, Morphogenesis"
330	"Binding, VEGF-A"	leads to	"Decreased, VegfR2"
331	"Binding, VEGF-A"	leads to	"Inhibition, VegfR2"
332	"Production, VEGF-A"	leads to	"Binding, VEGF-A"
333	"Production, VEGF-A"	leads to	"Decreased, VegfR2"
334	"Decreased, VegfR2"	leads to	"Inhibition, VegfR2"
335	"Inhibition, VegfR2"	leads to	"Reduction, Angiogenic sprouting"
336	"Increase, Vitellogenin synthesis in liver"	leads to	"Increase, Plasma vitellogenin concentrations"
337	"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"	leads to	"Reduction, Cumulative fecundity and spawning"
338	"Alteration, Wnt pathway"	leads to	"Feminisation or incomplete development, Primary and accessory male sex organs"
340	"Activation, Pre-MIE: Metabolism of AFB1"	leads to	"Formation, Pro-mutagenic DNA Adducts"
342	"Increased, Induced Mutations in Critical Genes"	leads to	"Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H"
343	"Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H"	leads to	"Tumorigenesis, Hepatocellular carcinoma"
344	"Formation, Pro-mutagenic DNA Adducts"	leads to	"Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H"
345	"Formation, Pro-mutagenic DNA Adducts"	leads to	"Tumorigenesis, Hepatocellular carcinoma"
346	"Increased, Induced Mutations in Critical Genes"	leads to	"Tumorigenesis, Hepatocellular carcinoma"
347	"Decreased, Calcium influx"	leads to	"Reduced, Release of BDNF"
348	"Reduced, Release of BDNF"	leads to	"Aberrant, Dendritic morphology"
350	"Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci"	leads to	"Tumorigenesis, Hepatocellular carcinoma"
351	"Increased, Induced Mutations in Critical Genes"	leads to	"Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci"
352	"Formation, Pro-mutagenic DNA Adducts"	leads to	"Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci"
353	"Reduced, Release of BDNF"	leads to	"N/A, Cell injury/death"
354	"Reduced, Release of BDNF"	leads to	"Reduced, Presynaptic release of glutamate"
355	"N/A, Cell injury/death"	leads to	"Decreased, Synaptogenesis"
356	"Aberrant, Dendritic morphology"	leads to	"Decreased, Synaptogenesis"
357	"Reduced, Presynaptic release of glutamate"	leads to	"Decreased, Synaptogenesis"
358	"Decreased, Synaptogenesis"	leads to	"Decreased, Neuronal network function in developing brain"
359	"Decreased, Neuronal network function in developing brain"	leads to	"Impairment, Learning and memory"
360	"Binding of agonist, NMDARs"	leads to	"Overactivation, NMDARs"
361	"Overactivation, NMDARs"	leads to	"Increased, Intracellular Calcium overload"
362	"Increased, Intracellular Calcium overload"	leads to	"N/A, Mitochondrial dysfunction 1"
363	"N/A, Mitochondrial dysfunction 1"	leads to	"N/A, Cell injury/death"
364	"N/A, Cell injury/death"	leads to	"N/A, Neurodegeneration"
365	"N/A, Cell injury/death"	leads to	"N/A, Neuroinflammation"
366	"Thyroperoxidase, Inhibition"	leads to	"Thyroxine (T4) in serum, Decreased"
368	"N/A, Neurodegeneration"	leads to	"Decreased, Neuronal network function in developing brain"
369	"Activation, PPAR?"	leads to	"Decrease, Steroidogenic acute regulatory protein (STAR)"
370	"Activation, PPAR?"	leads to	"Decrease, Translocator protein (TSPO)"
376	"Covalent Binding, Protein"	leads to	"Response, Keratinocytes"
377	"Covalent Binding, Protein"	leads to	"Activation, Dendritic Cells"
378	"Response, Keratinocytes"	leads to	"Activation, Dendritic Cells"
379	"Activation, Dendritic Cells"	leads to	"Activation/Proliferation, T-cells"
380	"Response, Keratinocytes"	leads to	"Activation/Proliferation, T-cells"
381	"Induction, Upregulation of glucuronyltransferase activity"	leads to	"Decrease, Serum thyroxine (T4)"
382	"Increase, Biliary excretion TH glucuronide"	leads to	"Decrease, Serum thyroxine (T4)"
383	"Thyroperoxidase, Inhibition"	leads to	"Cognitive Function, Decreased"
384	"Altered, Neurophysiology"	leads to	"Cognitive Function, Decreased"
385	"Activation, Glucocorticoid Receptor"	leads to	"Induction, IKB inhibitory protein"
386	"Induction, IKB inhibitory protein"	leads to	"Inhibition, Nuclear factor kappa B (NF-kB)"
387	"Inhibition, Nuclear factor kappa B (NF-kB)"	leads to	"Suppression, Inflammatory cytokines"
388	"Suppression, Inflammatory cytokines"	leads to	"Decreased, Lymphocytes"
389	"Decreased, Lymphocytes"	leads to	"Increased, Disease susceptibility"
390	"Decreased, Lymphocytes"	leads to	"Suppression, Immune system"
392	"Reduction, Plasma 17beta-estradiol concentrations"	leads to	"irregularities, ovarian cycle"
393	"irregularities, ovarian cycle"	leads to	"Decreased, Fertility"
394	"irregularities, ovarian cycle"	leads to	"impaired, Fertility"
395	"Activation, PPAR?"	leads to	"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"
396	"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"	leads to	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
398	"Increase proliferation, Leydig cell"	leads to	"Hyperplasia, Leydig cell"
399	"Decrease, Translocator protein (TSPO)"	leads to	"Reduction, Testosterone synthesis in Leydig cells"
402	"Metabolism of AFB1, Production of Reactive Electrophiles"	leads to	"Formation, Pro-mutagenic DNA Adducts"
403	"Thyroxine (T4) in serum, Decreased"	leads to	"Cognitive Function, Decreased"
405	"Malformation, Male reproductive tract"	leads to	"impaired, Fertility"
411	"Activation, PPAR?"	leads to	"Up Regulation, CD36"
428	"Increased, Mortality"	leads to	"Decreased, Population trajectory"
432	"Increased, Atrioventricular block and bradycardia"	leads to	"Increased, Mortality"
433	"Increased, Respiratory distress/arrest"	leads to	"Increased, Mortality"
434	"Induction, Ataxia, paralysis, or hyperactivity"	leads to	"Increased, Mortality"
436	"Decrease, Steroidogenic acute regulatory protein (STAR)"	leads to	"Reduction, Cholesterol transport in mitochondria"
437	"Decrease, Translocator protein (TSPO)"	leads to	"Reduction, Cholesterol transport in mitochondria"
438	"Reduction, Cholesterol transport in mitochondria"	leads to	"Reduction, Testosterone synthesis in Leydig cells"
439	"Reduction, Testosterone synthesis in Leydig cells"	leads to	"Reduction, testosterone level"
442	"Inhibition, Na+/I- symporter (NIS)"	leads to	"Decreased, Thyroidal iodide uptake"
443	"Decreased, Thyroidal iodide uptake"	leads to	"Thyroxine (T4) in serum, Decreased"
444	"Thyroxine (T4) in neuronal tissue, Decreased"	leads to	"Reduced, Release of BDNF"
445	"Reduced, Release of BDNF"	leads to	"Down Regulation, K-Cl co-transporter 2 (KCC2)"
446	"Down Regulation, K-Cl co-transporter 2 (KCC2)"	leads to	"Delay, Developmental GABA shift"
447	"Delay, Developmental GABA shift"	leads to	"Decreased, Synaptogenesis"
448	"Reduced, Release of BDNF"	leads to	"Decreased, Synaptogenesis"
449	"Inhibition, Acetylcholinesterase (AchE)"	leads to	"Increased, Atrioventricular block and bradycardia"
450	"Inhibition, Acetylcholinesterase (AchE)"	leads to	"Increased, Respiratory distress/arrest"
451	"Inhibition, Acetylcholinesterase (AchE)"	leads to	"Induction, Ataxia, paralysis, or hyperactivity"
452	"Inhibition, Acetylcholinesterase (AchE)"	leads to	"Increased, Mortality"
453	"Inhibition, Acetylcholinesterase (AchE)"	leads to	"Decreased, Population trajectory"
454	"Accumulation, Acetylcholine in synapses"	leads to	"Increased, Atrioventricular block and bradycardia"
456	"Accumulation, Acetylcholine in synapses"	leads to	"Induction, Ataxia, paralysis, or hyperactivity"
457	"Induction, Ataxia, paralysis, or hyperactivity"	leads to	"Increased, Respiratory distress/arrest"
459	"Accumulation, Acetylcholine in synapses"	leads to	"Inhibition, Acetylcholinesterase (AchE)"
460	"Reduction, testosterone level"	leads to	"Increase, Luteinizing hormone (LH)"
461	"Increase, Luteinizing hormone (LH)"	leads to	"Increase proliferation, Leydig cell"
462	"Hyperplasia, Leydig cell"	leads to	"impaired, Fertility"
470	"Inhibition, Mitochondrial fatty acid beta-oxidation"	leads to	"Accumulation, Liver lipid"
471	"Suppression, VLDL secretion"	leads to	"Accumulation, Liver lipid"
472	"Accumulation, Fatty acid"	leads to	"Accumulation, Triglyceride"
473	"Activation, AHR"	leads to	"Inhibition, Mitochondrial fatty acid beta-oxidation"
474	"Accumulation, Triglyceride"	leads to	"Accumulation, Liver lipid"
475	"Inhibition, Mitochondrial fatty acid beta-oxidation"	leads to	"Accumulation, Fatty acid"
476	"Suppression, Constitutive androstane receptor, NR1l3"	leads to	"Activation, LXR"
477	"Suppression, Constitutive androstane receptor, NR1l3"	leads to	"Activation, PPAR?"
478	"Activation, LXR"	leads to	"Increased, Fatty acid uptake"
479	"Activation, LXR"	leads to	"Activation, SREBF1"
480	"Increased, De Novo FA synthesis"	leads to	"Increased, Liver Steatosis"
481	"Increased, Fatty acid uptake"	leads to	"Increased, Liver Steatosis"
482	"Activation, SREBF1"	leads to	"Increased, De Novo FA synthesis"
483	"Activation, ChREBP"	leads to	"Increased, De Novo FA synthesis"
484	"Increased, De Novo FA synthesis"	leads to	"Increased, Triglyceride formation"
485	"Increased, Fatty acid uptake"	leads to	"Increased, Triglyceride formation"
486	"Increased, Triglyceride formation"	leads to	"Increased, Liver Steatosis"
487	"Activation, PPAR?"	leads to	"Activation, SREBF1"
488	"Activation, PPAR?"	leads to	"Increased, Fatty acid uptake"
489	"Activation, SREBF1"	leads to	"Up Regulation, SCD-1"
490	"Activation, LXR"	leads to	"Up Regulation, FAS"
491	"Activation, LXR"	leads to	"Up Regulation, SCD-1"
492	"Up Regulation, FAS"	leads to	"Increased, De Novo FA synthesis"
493	"Up Regulation, SCD-1"	leads to	"Increased, Triglyceride formation"
494	"Up Regulation, CD36"	leads to	"Increased, Fatty acid uptake"
495	"Activation, AHR"	leads to	"Up Regulation, CD36"
496	"Activation, AHR"	leads to	"Increased, FA Influx"
497	"Activation, AHR"	leads to	"Increased, SCD-1"
499	"Activation, AHR"	leads to	"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"
500	"Increased, SCD-1"	leads to	"Accumulation, Triglyceride"
501	"Up Regulation, CD36"	leads to	"Increased, FA Influx"
502	"Accumulation, Fatty acid"	leads to	"Accumulation, Liver lipid"
503	"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"	leads to	"Accumulation, Fatty acid"
504	"Increased, FA Influx"	leads to	"Accumulation, Triglyceride"
505	"Increased, FA Influx"	leads to	"Accumulation, Fatty acid"
506	"Activation, AHR"	leads to	"Up Regulation, LDLR (low density lipoprotein receptor)"
507	"Up Regulation, LDLR (low density lipoprotein receptor)"	leads to	"Increased, LDL uptake"
508	"Increased, LDL uptake"	leads to	"Accumulation, Fatty acid"
509	"Activation, AHR"	leads to	"Suppression, VLDL secretion"
510	"Activation, LXR"	leads to	"Inhibition, PPAR alpha"
511	"Inhibition, PPAR alpha"	leads to	"Inhibition, Mitochondrial fatty acid beta-oxidation"
512	"Increased, De Novo FA synthesis"	leads to	"Accumulation, Fatty acid"
513	"Increased, Fatty acid uptake"	leads to	"Accumulation, Fatty acid"
514	"Accumulation, Fatty acid"	leads to	"Increased, Triglyceride formation"
515	"Accumulation, Fatty acid"	leads to	"Increased, Liver Steatosis"
516	"Activation, LXR"	leads to	"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"
517	"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"	leads to	"Increased, De Novo FA synthesis"
518	"Activation, PXR/SXR"	leads to	"Inhibition, FoxA2"
519	"Inhibition, FoxA2"	leads to	"Down Regulation, CPT1A"
520	"Down Regulation, CPT1A"	leads to	"Decreased, Mitochondrial fatty acid beta-oxidation"
521	"Decreased, Mitochondrial fatty acid beta-oxidation"	leads to	"Accumulation, Hepatic FA"
522	"Accumulation, Hepatic FA"	leads to	"Increased, Liver Steatosis"
523	"Inhibition, FoxA2"	leads to	"Down Regulation, HMGCS2"
524	"Down Regulation, HMGCS2"	leads to	"Decreased, Ketogenesis"
525	"Decreased, Ketogenesis"	leads to	"Accumulation, Hepatic FA"
526	"Activation, PXR/SXR"	leads to	"Up Regulation, SCD-1"
527	"Up Regulation, SCD-1"	leads to	"Increased, Hepatic Triglycerides"
528	"Increased, Hepatic Triglycerides"	leads to	"Increased, Liver Steatosis"
529	"Activation, PXR/SXR"	leads to	"Up Regulation, CD36"
530	"Increased, FA Influx"	leads to	"Increased, Hepatic Triglycerides"
531	"Increased, FA Influx"	leads to	"Accumulation, Hepatic FA"
532	"Activation, NRF2"	leads to	"Activation, NR1H4"
533	"Activation, NR1H4"	leads to	"Activation, SHP"
534	"Activation, NR1H4"	leads to	"Activation, PPAR?"
535	"Activation, PPAR?"	leads to	"Activation, LXR alpha"
536	"Activation, LXR alpha"	leads to	"Increased, De Novo FA synthesis"
537	"Decreased, DHB4/HSD17B4"	leads to	"Inhibition, Mitochondrial fatty acid beta-oxidation"
538	"Inhibition, Mitochondrial fatty acid beta-oxidation"	leads to	"Increased, Liver Steatosis"
539	"Activation, AKT2"	leads to	"Activtation, SREBP-1c"
540	"Activtation, SREBP-1c"	leads to	"Increased, Liver Steatosis"
541	inflammation	leads to	"Activation, AKT2"
544	"Decrease, Ovulation"	leads to	"Reduction, Cumulative fecundity and spawning"
547	"Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts"	leads to	"Increased, Induced Mutations in Critical Genes"
548	"Formation, Pro-mutagenic DNA Adducts"	leads to	"Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts"
549	"Increased, Induced Mutations in Critical Genes"	leads to	"Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"
550	"Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"	leads to	"Tumorigenesis, Hepatocellular carcinoma"
551	"Formation, Pro-mutagenic DNA Adducts"	leads to	"Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"
552	"Inhibition, Na+/I- symporter (NIS)"	leads to	"Thyroid hormone synthesis, Decreased"
558	"Reduced, Food storage"	leads to	"Decrease, Number of worker bees"
559	"Decrease, Number of worker bees"	leads to	"Death/Failure, Colony"
562	"Reduced, Food storage"	leads to	"impaired, Larval development"
563	"impaired, Larval development"	leads to	"Death/Failure, Colony"
564	"Impairment, Learning and memory"	leads to	"Abnormal, Roll change within caste"
565	"Abnormal, Roll change within caste"	leads to	"Reduced, Brood care"
566	"Reduced, Brood care"	leads to	"impaired, Larval development"
567	"Increase, Energetic demands and therefore metabolic stress"	leads to	"Increased, Appetite and hunger"
568	"Increased, Appetite and hunger"	leads to	"Abnormal, Foraging activity and behavior"
569	"Abnormal, Foraging activity and behavior"	leads to	"Decrease, Number of worker bees"
570	"Suppression, Immune system"	leads to	"Increased, Viral susceptibility"
571	"Increased, Viral susceptibility"	leads to	"impaired, Development"
572	"impaired, Development"	leads to	"Decrease, Number of worker bees"
573	"Decrease, Number of worker bees"	leads to	"impaired, Hive thermoregulation"
574	"impaired, Hive thermoregulation"	leads to	"Death/Failure, Colony"
575	"Increased, Viral susceptibility"	leads to	"Abnormal, Foraging activity and behavior"
576	"Decreased, Glucose oxidase enzyme activity"	leads to	"Decreased, Hydrogen peroxide production"
577	"Decreased, Hydrogen peroxide production"	leads to	"Reduced, Antiseptic incorporated in food"
578	"Reduced, Antiseptic incorporated in food"	leads to	"Abnormal, Roll change within caste"
579	"Abnormal, Roll change within caste"	leads to	"Reduced, Food storage"
580	"Abnormal, Roll change within caste"	leads to	"Decrease, Number of worker bees"
581	"Activation, Nicotinic acetylcholine receptor"	leads to	"N/A, Mitochondrial dysfunction 1"
582	"N/A, Mitochondrial dysfunction 1"	leads to	"Decreased, Neuronal network function in developing brain"
583	"Impairment, Learning and memory"	leads to	"Abnormal, Foraging activity and behavior"
584	"Abnormal, Foraging activity and behavior"	leads to	"Reduced, Food storage"
585	"Inhibition, sodium channel"	leads to	"Decreased, Sodium conductance 1"
586	"Decreased, Sodium conductance 1"	leads to	"Reduced, swimming speed"
587	"Reduced, swimming speed"	leads to	"Reduced, feeding 1"
588	"Reduced, swimming speed"	leads to	"Increased, predation"
589	"Reduced, feeding 1"	leads to	"Increased, predation"
590	"Inhibition, sodium channel"	leads to	"Increased, Atrioventricular block and bradycardia"
591	"Increased, Atrioventricular block and bradycardia"	leads to	"Increased, Respiratory distress/arrest"
592	"Increased, Respiratory distress/arrest"	leads to	"N/A, hypoxia"
593	"N/A, hypoxia"	leads to	"Increased, amputations"
594	"Decreased, Sodium conductance 1"	leads to	"Increased, Atrioventricular block and bradycardia"
595	"Increased, predation"	leads to	"Reduced, survival"
596	"Reduced, feeding 1"	leads to	"Reduced, survival"
597	"Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel"	leads to	"Decreased, Sodium conductance 1"
603	"modulation, sodium channel"	leads to	"prolonged, Depolarization of neuronal membrane"
604	"prolonged, Depolarization of neuronal membrane"	leads to	"Overactivation, Neuronotransmitter release"
605	"Overactivation, Neuronotransmitter release"	leads to	"Overactivation, muscle contraction"
606	"Overactivation, muscle contraction"	leads to	"Increased, Ataxia, paralysis, or hyperactivity"
607	"Increased, Ataxia, paralysis, or hyperactivity"	leads to	"Increased, Mortality"
608	"Reduction, testosterone level"	leads to	"Malformation, Male reproductive tract"
617	"Decreased, Mitochondrial fatty acid beta-oxidation"	leads to	"Increased, Liver Steatosis"
630	"Occurrence, A paroxysmal depolarizing shift"	leads to	"Occurrence, Epileptic seizure"
634	"Decreased, Neuronal network function in adult brain"	leads to	"Impairment, Learning and memory"
635	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	"Increased, serotonin (5-HT) 1"
636	"Increased, serotonin (5-HT) 1"	leads to	"Increase, cilia movement"
637	"Increase, cilia movement"	leads to	"Increased, locomotion"
638	"Increased, locomotion"	leads to	"Increase, predation"
639	"Increase, cilia movement"	leads to	"Increased, foot detachment"
640	"Increased, serotonin (5-HT) 1"	leads to	"Increased, muscular waves in foot"
641	"Increased, muscular waves in foot"	leads to	"Increased, locomotion"
642	"Increased, muscular waves in foot"	leads to	"Increased, foot detachment"
643	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	"Increased, serotonin (5-HT)"
644	"Increased, serotonin (5-HT)"	leads to	"Decreased, anxiety"
645	"Decreased, anxiety"	leads to	"Decreased, sheltering"
646	"Decreased, sheltering"	leads to	"Increased, predation"
647	"N/A, Neurodegeneration"	leads to	"Decreased, Neuronal network function in adult brain"
649	"Decrease, histaminergic neuron excitation"	leads to	"N/A, sedation"
650	"N/A, sedation"	leads to	"Decreased, locomotion"
651	"Decreased, locomotion"	leads to	"Increased, predation"
652	"Decrease, histaminergic neuron excitation"	leads to	"impaired, Learning and memory"
653	"impaired, Learning and memory"	leads to	"Decreased, locomotion"
654	"Increased, predation"	leads to	"Decreased, survival"
656	"Decreased, Synaptogenesis"	leads to	"N/A, Neuroinflammation"
658	"Activation, Nicotinic acetylcholine receptor"	leads to	"Desensitization, Nicotinic acetylcholine receptor"
659	"Desensitization, Nicotinic acetylcholine receptor"	leads to	"Decreased, Neuronal network function in developing brain"
660	"N/A, Mitochondrial dysfunction 1"	leads to	"Overwhelmed, Mitochondrial DNA repair mechanisms"
661	"Overwhelmed, Mitochondrial DNA repair mechanisms"	leads to	"Accumulation, Damaged mitochondrial DNA"
662	"Accumulation, Damaged mitochondrial DNA"	leads to	"Accelerated, Aging"
663	"Accelerated, Aging"	leads to	"Decrease, Number of worker bees"
664	"N/A, Mitochondrial dysfunction 1"	leads to	"impaired, Thoracic shivering"
665	"impaired, Thoracic shivering"	leads to	"impaired, Hive thermoregulation"
666	"Binding at picrotoxin site, iGABAR chloride channel"	leads to	"Reduction, Ionotropic GABA receptor chloride channel conductance"
667	"Reduction, Ionotropic GABA receptor chloride channel conductance"	leads to	"Reduction, Neuronal synaptic inhibition"
670	"Inhibition, Cyclooxygenase activity"	leads to	"Reduced, Prostaglandin F2alpha synthesis, ovary"
671	"Reduced, Prostaglandin F2alpha synthesis, ovary"	leads to	"Reduced, Prostaglandin F2alpha concentration, plasma"
672	"Reduced, Prostaglandin F2alpha concentration, plasma"	leads to	"Reduced, Spawning behavior"
673	"Reduced, Spawning behavior"	leads to	"Reduced, Ability to attract spawning mates"
674	"Reduced, Ability to attract spawning mates"	leads to	"Reduced, Reproductive Success"
675	"Reduced, Reproductive Success"	leads to	"Decrease, Population trajectory"
678	"Reduced, Prostaglandin F2alpha concentration, plasma"	leads to	"Reduced, Pheromone release"
679	"Reduced, Pheromone release"	leads to	"Reduced, Ability to attract spawning mates"
680	"Reduced, Reproductive Success"	leads to	"Decline, Population trajectory"
681	"Inhibition, Cyclooxygenase activity"	leads to	"Decreased, Prostaglandin F2alpha synthesis, ovary"
682	"Decreased, Prostaglandin F2alpha synthesis, ovary"	leads to	"Reduced, Prostaglandin F2alpha concentration, plasma"
683	"Reduction, Neuronal synaptic inhibition"	leads to	"Generation, Amplified excitatory postsynaptic potential (EPSP)"
684	"Generation, Amplified excitatory postsynaptic potential (EPSP)"	leads to	"Occurrence, A paroxysmal depolarizing shift"
685	"Reduced, Prostaglandins, ovary"	leads to	"Decrease, Ovulation"
686	"Inhibition, Cyclooxygenase activity"	leads to	"Reduced, Prostaglandins, ovary"
687	"Decrease, Ovulation"	leads to	"Reduced, Reproductive Success"
688	"Reduced, Reproductive Success"	leads to	"Declining, Population trajectory"
689	"Inhibition, Cyclooxygenase activity"	leads to	"Reduced, Prostaglandin E2 concentration, hypothalamus"
690	"Reduced, Prostaglandin E2 concentration, hypothalamus"	leads to	"Reduced, Gonadotropin releasing hormone, hypothalamus"
691	"Reduced, Gonadotropin releasing hormone, hypothalamus"	leads to	"Reduced, Luteinizing hormone (LH), plasma"
692	"Reduced, Luteinizing hormone (LH), plasma"	leads to	"Reduced, Maturation inducing steroid, plasma"
693	"Reduced, Maturation inducing steroid, plasma"	leads to	"Reduced, Maturation inducing steroid receptor signalling, oocyte"
694	"Reduced, Maturation inducing steroid receptor signalling, oocyte"	leads to	"Increased, cyclic adenosine monophosphate"
695	"Increased, cyclic adenosine monophosphate"	leads to	"Reduced, Reproductive Success"
696	"Increased, cyclic adenosine monophosphate"	leads to	"Reduced, Meiotic prophase I/metaphase I transition, oocyte"
697	"Reduced, Meiotic prophase I/metaphase I transition, oocyte"	leads to	"Reduced, Reproductive Success"
698	"Reduced, Maturation inducing steroid receptor signalling, oocyte"	leads to	"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"
699	"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"	leads to	"Increased, Chromosome misseggregation"
700	"Increased, Chromosome misseggregation"	leads to	"Reduced, Reproductive Success"
701	"impaired, ion channels"	leads to	"Altered, Action Potential"
702	"Altered, Action Potential"	leads to	"Increased, cardiac arrthymia"
703	"Increased, cardiac arrthymia"	leads to	"Increased, Mortality"
706	"Increased, Binding of chemicals to 2u (serum)"	leads to	"Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)"
707	"Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)"	leads to	"Increase, Cytotoxicity (renal tubular cell)"
708	"Increase, Cytotoxicity (renal tubular cell)"	leads to	"Increase, Regenerative cell proliferation (tubular epithelial cells)"
711	"Activation, Constitutive androstane receptor"	leads to	"Increase, Mitogenic cell proliferation (hepatocytes)"
714	"Binding, Tubulin"	leads to	"Depolymerization, Microtubule"
715	"Depolymerization, Microtubule"	leads to	"Disorganization, Spindle"
716	"Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme"	leads to	"Increased, Induction of pyruvate dehydrogenase (PDH)"
723	"Altered, Chromosome number"	leads to	"Increase, Aneuploid offspring"
724	"Binding, Tubulin"	leads to	"Altered, Chromosome number"
726	"Increase, Necrosis (terminal bronchiolar cells)"	leads to	"Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)"
727	"Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)"	leads to	"Increase, Hyperplasia (terminal bronchiolar cells)"
728	"Increase, Hyperplasia (terminal bronchiolar cells)"	leads to	"Increase, Adenomas/carcinomas (bronchioloalveolar)"
729	"Decreased, Androgen receptor activity"	leads to	"Decreased, Testosterone binding to androgen receptor (hypothalamus)"
730	"Decreased, Testosterone binding to androgen receptor (hypothalamus)"	leads to	"Increase, Hyperplasia (Leydig cells)"
731	"Increase, Hyperplasia (Leydig cells)"	leads to	"Increase, Leydig cell tumors"
732	"Increase, Dopaminergic activity"	leads to	"Decreased, Prolactin"
733	"Decreased, Prolactin"	leads to	"Increased, Estrogen receptor (ER) activity"
734	"Increased, Estrogen receptor (ER) activity"	leads to	"Decreased, Progesterone from corpus luteum"
737	"Disorganization, Spindle"	leads to	"Altered, Meiotic chromosome dynamics"
738	"Altered, Meiotic chromosome dynamics"	leads to	"Altered, Chromosome number"
741	"Increase, Thyroid-stimulating hormone (TSH)"	leads to	"Increase, Hypertrophy and proliferation (follicular cell)"
742	"Increase, Hypertrophy and proliferation (follicular cell)"	leads to	"Increase, Hyperplasia (follicular cells)"
743	"Increase, Hyperplasia (follicular cells)"	leads to	"Increase, Adenomas/carcinomas (follicular cell)"
744	"Decreased, Testosterone binding to androgen receptor (hypothalamus)"	leads to	"Increased, Luteinizing hormone (LH)"
745	"Increased, Luteinizing hormone (LH)"	leads to	"Increase, Hyperplasia (Leydig cells)"
746	"Thyroxine (T4) in neuronal tissue, Decreased"	leads to	"Hippocampal gene expression, Altered"
747	"Hippocampal gene expression, Altered"	leads to	"Hippocampal anatomy, Altered"
748	"Hippocampal Physiology, Altered"	leads to	"Cognitive Function, Decreased"
749	"Hippocampal anatomy, Altered"	leads to	"Hippocampal Physiology, Altered"
750	"Activation, 5HT2c"	leads to	"N/A, Unknown"
751	"N/A, Unknown"	leads to	"Increased, Kidney Failure"
752	"Activation, Glutamate-gated chloride channel"	leads to	"Increased, Chloride conductance"
755	"hyperpolarisation, neuron"	leads to	"N/A, Ataxia, paralysis, or hyperactivity"
756	"Increased, Mortality"	leads to	"Decreased, population 1"
757	"N/A, Ataxia, paralysis, or hyperactivity"	leads to	"Increased, Mortality"
758	"Increased, Chloride conductance"	leads to	"hyperpolarisation, neuron"
759	"N/A, Neuroinflammation"	leads to	"Decreased, Synaptogenesis"
760	"Increase, Regenerative cell proliferation (tubular epithelial cells)"	leads to	"Increase, Hyperplasia (renal tubular cells)"
761	"Increase, Hyperplasia (renal tubular cells)"	leads to	"Increase, Adenomas/carcinomas (renal tubular)"
762	"Increased, Induction of pyruvate dehydrogenase (PDH)"	leads to	"Increase, Oxidative metabolism"
763	"Increase, Oxidative metabolism"	leads to	"Increase, Oxidative Stress"
764	"Increase, Oxidative Stress"	leads to	"Increase, Adenomas/carcinomas (hepatocellular)"
765	"Increase, Oxidative Stress"	leads to	"Increase, Cytotoxicity"
766	"Increase, Cytotoxicity"	leads to	"Increase, Adenomas/carcinomas (hepatocellular)"
767	"Increase, Cytotoxicity (club cells)"	leads to	"Increase, Necrosis (terminal bronchiolar cells)"
768	"Decreased, Uptake of inorganic iodide"	leads to	"Decrease, Serum thyroid hormone (T4/T3)"
769	"Decrease, Serum thyroid hormone (T4/T3)"	leads to	"Increase, Thyroid-stimulating hormone (TSH)"
770	"Increase, Dopaminergic activity"	leads to	"Increase, Endometrial adenocarcinomas"
771	"Increase, Hyperplasia (glandular epithelial cells of endometrium)"	leads to	"Increase, Endometrial adenocarcinomas"
772	"Decreased, Progesterone from corpus luteum"	leads to	"Increase, Hyperplasia (glandular epithelial cells of endometrium)"
773	"Increase, Mitogenic cell proliferation (hepatocytes)"	leads to	"Increase, Preneoplastic foci (hepatocytes)"
774	"Increase, Preneoplastic foci (hepatocytes)"	leads to	"Increase, Adenomas/carcinomas (hepatocellular)"
775	"Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme"	leads to	"Increased, Plasma tyrosine"
776	"Increased, Plasma tyrosine"	leads to	"Increase, Cytotoxicity (corneal cells)"
777	"Increase, Cytotoxicity (corneal cells)"	leads to	"Increase, Inflammation (corneal cells)"
778	"Increase, Inflammation (corneal cells)"	leads to	"Increase, Regenerative cell proliferation (corneal cells)"
779	"Increase, Regenerative cell proliferation (corneal cells)"	leads to	"Increase, Papillomas/carcinomas (squamous cells)"
780	"Increase, Cytotoxicity (epithelial cells)"	leads to	"Increase, Inflammation"
781	"Increase, Inflammation"	leads to	"Increase, Regenerative cell proliferation (forestomach epithelial cells)"
782	"Increase, Regenerative cell proliferation (forestomach epithelial cells)"	leads to	"Increase, Hyperplasia (forestomach epithelial cells)"
783	"Increase, Hyperplasia (forestomach epithelial cells)"	leads to	"Increase, Papillomas/carcinomas (squamous cells)"
784	"Increase, Cytotoxicity (tubular epithelial cells)"	leads to	"Increase, Regenerative cell proliferation (tubular epithelial cells)"
785	"Increase, Regenerative cell proliferation (tubular epithelial cells)"	leads to	"Increase, Hyperplasia (tubular epithelial cells)"
786	"Increase, Hyperplasia (tubular epithelial cells)"	leads to	"Increase, Adenomas/carcinomas (renal tubular)"
787	"Activation, Androgen receptor"	leads to	"Increase, Mitogenic cell proliferation (hepatocytes)"
788	"Increase, Cytotoxicity (hepatocytes)"	leads to	"Increase, Regenerative cell proliferation (hepatocytes)"
789	"Increase, Regenerative cell proliferation (hepatocytes)"	leads to	"Increase, Preneoplastic foci (hepatocytes)"
790	"Thyroperoxidase, Inhibition"	leads to	"Decrease, Incorporation of active iodide into iodotyrosines"
791	"Decrease, Incorporation of active iodide into iodotyrosines"	leads to	"Decrease, Serum thyroid hormone (T4/T3)"
792	"Inhibition, 5?-reductase activity"	leads to	"Decrease, Bioactivation of testosterone"
793	"Decrease, Bioactivation of testosterone"	leads to	"Increased, Leutinizing hormone (LH)"
794	"Increased, Leutinizing hormone (LH)"	leads to	"Increase, Hyperplasia (Leydig cells)"
795	"Increase, Urinary bladder calculi"	leads to	"Increase, Cytotoxicity (urothelial cells)"
796	"Increase, Cytotoxicity (urothelial cells)"	leads to	"Increase, Regenerative cell proliferation (urothelial cells)"
797	"Increase, Regenerative cell proliferation (urothelial cells)"	leads to	"Increase, Hyperplasia (urothelial)"
798	"Increase, Hyperplasia (urothelial)"	leads to	"Increase, Adenomas/carcinomas (urothelial)"
799	"Inhibition, Prolyl hydroxylases"	leads to	"Increased, HIF-1 heterodimer"
800	"Increased, HIF-1 heterodimer"	leads to	"Decreased, Aromatase (Cyp19a1) mRNA"
801	"Decreased, Aromatase (Cyp19a1) mRNA"	leads to	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
802	"modulation, Unknown"	leads to	"Increased, HIF-1 alpha transcription"
803	"Increased, HIF-1 alpha transcription"	leads to	"Increased, HIF-1 heterodimer"
804	"Inhibition, HMG-CoA reductase"	leads to	"Decreased, mevalonate"
805	"Decreased, mevalonate"	leads to	"Decreased, cholesterol"
806	"Decreased, cholesterol"	leads to	"Decreased, Testosterone"
807	"Decreased, Testosterone"	leads to	"malformed, Male reproductive tract"
808	"malformed, Male reproductive tract"	leads to	"Decreased, Fertility"
809	"Thyroid hormone synthesis, Decreased"	leads to	"Decreased, Thyroxine (T4) in serum"
810	"Thyroid hormone synthesis, Decreased"	leads to	"Increased, Serum creatinine"
811	"Decreased, Thyroxine (T4) in serum"	leads to	"Occurrence, Cytoplasmic vacuolization (Renal tubule)"
812	"Decreased, Thyroxine (T4) in serum"	leads to	"Occurrence, Cystic dilatation (renal tubule)"
813	"Increased, Serum creatinine"	leads to	"Occurrence, Cytoplasmic vacuolization (Renal tubule)"
814	"Increased, Serum creatinine"	leads to	"Occurrence, Cystic dilatation (renal tubule)"
815	"Decreased, Thyroxine (T4) in serum"	leads to	"Occurrence, Cytoplasmic vacuolization (podocyte)"
816	"Increased, Serum creatinine"	leads to	"Occurrence, Cytoplasmic vacuolization (podocyte)"
817	"Occurrence, Cytoplasmic vacuolization (Renal tubule)"	leads to	"Decreased, Glomerular filtration"
818	"Occurrence, Cytoplasmic vacuolization (Renal tubule)"	leads to	"Decreased, Renal plasma flow"
819	"Occurrence, Cytoplasmic vacuolization (Renal tubule)"	leads to	"Decreased, Sodium reabsorption"
820	"Occurrence, Cytoplasmic vacuolization (Renal tubule)"	leads to	"Decreased, Renal ability to dilute urine"
821	"Occurrence, Cystic dilatation (renal tubule)"	leads to	"Decreased, Glomerular filtration"
822	"Occurrence, Cystic dilatation (renal tubule)"	leads to	"Decreased, Renal plasma flow"
823	"Occurrence, Cystic dilatation (renal tubule)"	leads to	"Decreased, Sodium reabsorption"
824	"Occurrence, Cystic dilatation (renal tubule)"	leads to	"Decreased, Renal ability to dilute urine"
825	"Occurrence, Cytoplasmic vacuolization (podocyte)"	leads to	"Decreased, Glomerular filtration"
826	"Occurrence, Cytoplasmic vacuolization (podocyte)"	leads to	"Decreased, Renal plasma flow"
827	"Occurrence, Cytoplasmic vacuolization (podocyte)"	leads to	"Decreased, Sodium reabsorption"
828	"Occurrence, Cytoplasmic vacuolization (podocyte)"	leads to	"Decreased, Renal ability to dilute urine"
829	"Decreased, Glomerular filtration"	leads to	"Occurrence, Kidney toxicity"
830	"Decreased, Renal plasma flow"	leads to	"Occurrence, Kidney toxicity"
831	"Decreased, Sodium reabsorption"	leads to	"Occurrence, Kidney toxicity"
832	"Decreased, Renal ability to dilute urine"	leads to	"Occurrence, Kidney toxicity"
833	"Covalent Binding, Protein"	leads to	"Activation, Keratinocytes"
834	"Activation, Keratinocytes"	leads to	"Activation, Dendritic Cells"
835	"Activation/Proliferation, T-cells"	leads to	"sensitisation, skin"
836	"Inhibition, Phospholipase A"	leads to	"Damage, Lipid bilayer"
837	"Inhibition, Phospholipase A"	leads to	"Disturbance, Lysosomal function"
838	"Inhibition, Phospholipase A"	leads to	"Injury, Mitochondria"
839	"Damage, Lipid bilayer"	leads to	"Occurrence, Cytoplasmic vacuolization (hepatocyte)"
840	"Damage, Lipid bilayer"	leads to	"Occurrence, Ballooning degeneration (hepatocyte)"
841	"Damage, Lipid bilayer"	leads to	"Occurrence, Cytoplasmic vacuolization (Bile duct cell)"
842	"Damage, Lipid bilayer"	leads to	"Occurrence, Cytoplasmic vacuolization (kupffer cell)"
843	"Disturbance, Lysosomal function"	leads to	"Occurrence, Cytoplasmic vacuolization (hepatocyte)"
844	"Disturbance, Lysosomal function"	leads to	"Occurrence, Ballooning degeneration (hepatocyte)"
845	"Disturbance, Lysosomal function"	leads to	"Occurrence, Cytoplasmic vacuolization (Bile duct cell)"
846	"Disturbance, Lysosomal function"	leads to	"Occurrence, Cytoplasmic vacuolization (kupffer cell)"
847	"Injury, Mitochondria"	leads to	"Occurrence, Cytoplasmic vacuolization (hepatocyte)"
848	"Injury, Mitochondria"	leads to	"Occurrence, Ballooning degeneration (hepatocyte)"
849	"Injury, Mitochondria"	leads to	"Occurrence, Cytoplasmic vacuolization (Bile duct cell)"
850	"Injury, Mitochondria"	leads to	"Occurrence, Cytoplasmic vacuolization (kupffer cell)"
851	"Occurrence, Cytoplasmic vacuolization (hepatocyte)"	leads to	"Induction, Microvesicular fat"
852	"Occurrence, Cytoplasmic vacuolization (hepatocyte)"	leads to	"Formation, Mallory body"
853	"Occurrence, Ballooning degeneration (hepatocyte)"	leads to	"Induction, Microvesicular fat"
854	"Occurrence, Ballooning degeneration (hepatocyte)"	leads to	"Formation, Mallory body"
855	"Occurrence, Cytoplasmic vacuolization (Bile duct cell)"	leads to	"Induction, Microvesicular fat"
856	"Occurrence, Cytoplasmic vacuolization (Bile duct cell)"	leads to	"Formation, Mallory body"
857	"Occurrence, Cytoplasmic vacuolization (kupffer cell)"	leads to	"Induction, Microvesicular fat"
858	"Occurrence, Cytoplasmic vacuolization (kupffer cell)"	leads to	"Formation, Mallory body"
859	"Induction, Microvesicular fat"	leads to	"Formation, Liver fibrosis"
860	"Formation, Mallory body"	leads to	"Formation, Liver fibrosis"
864	"Oxidation, Uroporphyrinogen"	leads to	"Accumulation, Highly carboxylated porphyrins"
865	"Oxidation, Uroporphyrinogen"	leads to	"Inhibition, UROD"
866	"Accumulation, Highly carboxylated porphyrins"	leads to	Uroporphyria
867	"Inhibition, UROD"	leads to	"Oxidation, Uroporphyrinogen"
868	"Induction, CYP1A2/CYP1A5"	leads to	"Oxidation, Uroporphyrinogen"
869	"Activation, AHR"	leads to	"Induction, CYP1A2/CYP1A5"
870	"Reduced, Release of BDNF"	leads to	"Altered, GABAergic interneurons morphology and function"
871	"Altered, GABAergic interneurons morphology and function"	leads to	"Decreased, Synaptogenesis"
872	"Decreased, Thyroidal iodide uptake"	leads to	"Thyroid hormone synthesis, Decreased"
874	"Activation, Long term AHR receptor driven direct and indirect gene expression changes"	leads to	"Changes/Inhibition, Cellular Homeostasis and Apoptosis"
875	"Activation, Long term AHR receptor driven direct and indirect gene expression changes"	leads to	"Alterations, Cellular proliferation / hyperplasia"
876	"Activation, Long term AHR receptor driven direct and indirect gene expression changes"	leads to	"Formation, Hepatocellular and Bile duct tumors"
877	"Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain"	leads to	"Decreased, PPARalpha transactivation of gene expression"
878	"Decreased, PPARalpha transactivation of gene expression"	leads to	"Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids"
879	"Decreased, PPARalpha transactivation of gene expression"	leads to	"Decreased, Mitochondrial Fatty Acid Beta Oxidation"
880	"Decreased, PPARalpha transactivation of gene expression"	leads to	"Decreased, Ketogenesis (production of ketone bodies)"
881	"Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids"	leads to	"Decreased, Mitochondrial Fatty Acid Beta Oxidation"
882	"Decreased, Mitochondrial Fatty Acid Beta Oxidation"	leads to	"Decreased, Ketogenesis (production of ketone bodies)"
883	"Decreased, Ketogenesis (production of ketone bodies)"	leads to	"Not Increased, Circulating Ketone Bodies"
884	"Not Increased, Circulating Ketone Bodies"	leads to	"Increased, Catabolism of Muscle Protein"
885	"Increased, Catabolism of Muscle Protein"	leads to	"Decreased, Body Weight"
886	"Decrease, Intracellular pH"	leads to	"Increase, Cytotoxicity"
887	"Increase, Cytotoxicity"	leads to	"Increase, Tissue Degeneration, Necrosis & Atrophy"
888	"Increase, Tissue Degeneration, Necrosis & Atrophy"	leads to	"Increase, Respiratory or Squamous Metaplasia"
889	"Increase, Respiratory or Squamous Metaplasia"	leads to	"Increase, Cell Proliferation"
890	"Increase, Cell Proliferation"	leads to	"Increased, Induced Mutations in Critical Genes"
891	"Increased, Induced Mutations in Critical Genes"	leads to	"Increase, Site of Contact Nasal Tumors"
892	"Increased, Intracellular Calcium overload"	leads to	"Decreased, Neuronal network function in adult brain"
893	"Increase, Cell Proliferation"	leads to	"Increase, Mutations in Critical Genes"
894	"Increase, Mutations in Critical Genes"	leads to	"Increase, Site of Contact Nasal Tumors"
895	"Increase, Cell Proliferation"	leads to	"Increase, Site of Contact Nasal Tumors"
896	"Activation, SHP"	leads to	"Inhibition, SREBP1c"
899	"Increase, Mutations"	leads to	"Increase, Cancer"
901	"Alkylation, DNA"	leads to	"Increase, Cancer"
904	"N/A, Mitochondrial dysfunction 1"	leads to	"impaired, Proteostasis"
905	"impaired, Proteostasis"	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway
906	"N/A, Neuroinflammation"	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway
907	Degeneration of dopaminergic neurons of the nigrostriatal pathway	leads to	"N/A, Neuroinflammation"
908	"N/A, Mitochondrial dysfunction 1"	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway
910	Degeneration of dopaminergic neurons of the nigrostriatal pathway	leads to	Parkinsonian motor deficits
911	"Disruption, Lysosome"	leads to	"Increased, ROS production"
912	"Increased, ROS production"	leads to	"N/A, Mitochondrial dysfunction 1"
916	"Infiltration, Inflammatory cells"	leads to	"Inflammation, Liver"
919	"Binding of agonist, Ionotropic glutamate receptors"	leads to	"Overactivation, NMDARs"
921	"Disruption, Lysosome"	leads to	"Increase, Oxidative Stress"
922	"Increase, Oxidative Stress"	leads to	"N/A, Mitochondrial dysfunction 1"
923	"Increase, Oxidative Stress"	leads to	"Release, Cytokine"
924	"N/A, Cell injury/death"	leads to	"Release, Cytokine"
925	"Release, Cytokine"	leads to	"Infiltration, Inflammatory cytokines"
926	"Infiltration, Inflammatory cytokines"	leads to	"Inflammation, Liver"
927	"Inhibition, Bile Salt Export Pump (ABCB11)"	leads to	"Bile accumulation, Pathological condition"
928	"Bile accumulation, Pathological condition"	leads to	"Release, Cytokine"
929	"Increase, Inflammation"	leads to	"Cholestasis, Pathology"
930	"Bile accumulation, Pathological condition"	leads to	"Production, Reactive oxygen species"
931	"Production, Reactive oxygen species"	leads to	"Cholestasis, Pathology"
932	"Increase, Oxidative Stress"	leads to	"Cholestasis, Pathology"
933	"Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)"	leads to	"Inhibition, NADH-ubiquinone oxidoreductase (complex I)"
934	"Inhibition, NADH-ubiquinone oxidoreductase (complex I)"	leads to	"N/A, Mitochondrial dysfunction 1"
936	"Activation, Epidermal Growth Factor Receptor"	leads to	"Decrease, Apoptosis of ciliated epithelial cells"
939	"Activation, Epidermal Growth Factor Receptor"	leads to	"Increase, Proliferation of goblet cells"
942	"Activation, Epidermal Growth Factor Receptor"	leads to	"Increase, Transdifferentiation of ciliated epithelial cells"
943	"Increase, Transdifferentiation of ciliated epithelial cells"	leads to	"Increase, Metaplasia of goblet cells"
944	"Increase, Proliferation of goblet cells"	leads to	"Increase, Hyperplasia of goblet cells"
946	"Activation, Epidermal Growth Factor Receptor"	leads to	"Activation, SP1"
948	"Increase, Oxidative Stress"	leads to	"Oxidation, Glutathione"
952	"Decrease, GTPCH-1"	leads to	"Decrease, Tetrahydrobiopterin"
953	"Decrease, Tetrahydrobiopterin"	leads to	"Uncoupling, eNOS"
954	"Oxidation, Glutathione"	leads to	"S-Glutathionylation, eNOS"
955	"S-Glutathionylation, eNOS"	leads to	"Uncoupling, eNOS"
956	"Uncoupling, eNOS"	leads to	"Depletion, Nitric Oxide"
958	"Depletion, Nitric Oxide"	leads to	"impaired, Vasodilation"
961	"Decrease, Apoptosis of ciliated epithelial cells"	leads to	"Increase, Transdifferentiation of ciliated epithelial cells"
962	"Activation, EGFR"	leads to	"Decrease, Apoptosis of ciliated epithelial cells"
964	"Activation, EGFR"	leads to	"Activation, SP1"
965	"Activation, EGFR"	leads to	"Increase, Transdifferentiation of ciliated epithelial cells"
970	"Activation, EGFR"	leads to	"Increase, Proliferation of goblet cells"
972	"Activation, AHR"	leads to	"dimerization, AHR/ARNT"
973	"dimerization, AHR/ARNT"	leads to	"reduced dimerization, ARNT/HIF1-alpha"
974	"reduced dimerization, ARNT/HIF1-alpha"	leads to	"reduced production, VEGF"
975	"reduced production, VEGF"	leads to	"Impairment, Endothelial network"
976	"Impairment, Endothelial network"	leads to	"Altered, Cardiovascular development/function"
977	"Altered, Cardiovascular development/function"	leads to	"Increase, Pericardial edema"
978	"Increase, Pericardial edema"	leads to	"Increase, Embryolethality"
980	"Increase, Oxidative Stress"	leads to	"Decrease, GTPCH-1"
982	"impaired, Vasodilation"	leads to	"Increase, Vascular Resistance"
983	"Increase, Vascular Resistance"	leads to	"N/A, Hypertension"
984	"Activation, AHR"	leads to	"Increase, Embryolethality"
986	"Activation, EGFR"	leads to	"Increase, Mucin production"
987	"Activation, SP1"	leads to	"Increase, Mucin production"
988	"Decrease, Akt/eNOS activity"	leads to	"Depletion, Nitric Oxide"
989	"Increase, Hyperplasia of goblet cells"	leads to	"Hypersecretion, Mucus"
990	"Increase, Metaplasia of goblet cells"	leads to	"Hypersecretion, Mucus"
991	"Increase, Mucin production"	leads to	"Hypersecretion, Mucus"
992	"Increase, Oxidative Stress"	leads to	"Decrease, Akt/eNOS activity"
993	"Disruption, Lysosome"	leads to	"N/A, Mitochondrial dysfunction 1"
994	"Release, Cytokine"	leads to	"Infiltration, Inflammatory cells"
995	"Changes/Inhibition, Cellular Homeostasis and Apoptosis"	leads to	"N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"
996	"N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"	leads to	"Alterations, Cellular proliferation / hyperplasia"
997	"Alterations, Cellular proliferation / hyperplasia"	leads to	"Formation, Hepatocellular and Bile duct tumors"
998	"Activation, EcR"	leads to	"Reduction, Release of circulating ETH"
999	"Activation, EcR"	leads to	"Decreased, synthesis and secretion of molting fluid proteases"
1000	"Reduction, Release of circulating ETH"	leads to	"Induction, Incomplete ecdysis"
1001	"Decreased, synthesis and secretion of molting fluid proteases"	leads to	"Induction, Incomplete ecdysis"
1002	"Induction, Incomplete ecdysis"	leads to	"Increase, Mortality"
1003	"Decline, Population"	leads to	"Increased, Alterations of food-web structures"
1004	"Increase, Mortality"	leads to	"Decreased, population 1"
1005	"Decreased, population 1"	leads to	"Increased, Alterations of food-web structures"
1006	"Decline, Population"	leads to	"Alterations, Food-web structures"
1007	"Activation, EcR"	leads to	"Decreased, Synthesis of molting fluid proteases"
1008	"Reduction, Release of circulating ETH"	leads to	"Reduction, Abdominal muscle contraction"
1009	"Decreased, Synthesis of molting fluid proteases"	leads to	"Decreased, Digestion of old cuticle"
1010	"Reduction, Abdominal muscle contraction"	leads to	"Induction, Incomplete ecdysis"
1011	"Decreased, Digestion of old cuticle"	leads to	"Induction, Incomplete ecdysis"
1012	"Decreased, Population size"	leads to	"Alterations, Food-web structures"
1013	"Increase, Mortality"	leads to	"Decreased, Population size"
1015	"Binding, Formation, Binding of calcineurin with FK506-FKBP complexes"	leads to	"Activation, Suppression of NFAT activation and hindrance of nuclear localization"
1016	"Activation, Suppression of NFAT activation and hindrance of nuclear localization"	leads to	"Inhibition, Interference of NFAT complex formation at the site of nuclear cytokine promoter"
1017	"Inhibition, Interference of NFAT complex formation at the site of nuclear cytokine promoter"	leads to	"Suppression, Suppression of cytokine production in the presence of T-cell activation"
1018	"Suppression, Suppression of cytokine production in the presence of T-cell activation"	leads to	"Suppression, Suppression in mixed lymphocyte reaction (MLR)"
1019	"Suppression, Suppression of cytokine production in the presence of T-cell activation"	leads to	"Suppression, Suppression of T-cell dependent antibody response (TDAR)"
1020	"Suppression, Suppression of cytokine production in the presence of T-cell activation"	leads to	"Suppression, Suppression of transplant rejection"
1021	"Suppression, Suppression of cytokine production in the presence of T-cell activation"	leads to	"Relief, Relief of atopic dermatitis"
1022	"Suppression, Suppression of cytokine production in the presence of T-cell activation"	leads to	"Increase, Increased susceptibility to infection"
1023	"Binding of antagonist, PPAR alpha"	leads to	"stabilization, PPAR alpha co-repressor"
1024	"stabilization, PPAR alpha co-repressor"	leads to	"Decreased, PPARalpha transactivation of gene expression"
1025	"Abnormal, Morphogenesis"	leads to	"Increased, Developmental Defects"
1026	"Inhibition, Deiodinase 2"	leads to	"Decreased, Triiodothyronine (T3) in serum"
1027	"Decreased, Triiodothyronine (T3) in serum"	leads to	"Reduced, Posterior swim bladder inflation"
1028	"Reduced, Posterior swim bladder inflation"	leads to	"Reduced, Swimming performance"
1029	"Reduced, Swimming performance"	leads to	"Reduced, Young of year survival"
1030	"Reduced, Young of year survival"	leads to	"Decrease, Population trajectory"
1031	"Reduced, Posterior swim bladder inflation"	leads to	"Reduced, Anterior swim bladder inflation"
1032	"Reduced, Anterior swim bladder inflation"	leads to	"Reduced, Hearing"
1033	"Reduced, Hearing"	leads to	"Reduced, Young of year survival"
1034	"Reduced, Anterior swim bladder inflation"	leads to	"Reduced, Swimming performance"
1035	"Decreased, Triiodothyronine (T3) in serum"	leads to	"Reduced, Anterior swim bladder inflation"
1036	"Insufficiency, Vascular"	leads to	"Increased, Developmental Defects"
1037	"Inhibition, Deiodinase 1"	leads to	"Decreased, Triiodothyronine (T3) in serum"
1039	"Thyroxine (T4) in serum, Decreased"	leads to	"Reduced, Anterior swim bladder inflation"
1040	"Thyroperoxidase, Inhibition"	leads to	"Reduced, Anterior swim bladder inflation"
1041	"Reduced, Posterior swim bladder inflation"	leads to	"Reduced, Young of year survival"
1042	"Inhibition, Deiodinase 2"	leads to	"Reduced, Posterior swim bladder inflation"
1043	"Inhibition, Deiodinase 2"	leads to	"Reduced, Anterior swim bladder inflation"
1044	"Inhibition, Deiodinase 1"	leads to	"Reduced, Posterior swim bladder inflation"
1045	"Inhibition, Deiodinase 1"	leads to	"Reduced, Anterior swim bladder inflation"
1047	"Increased, Chloride influx"	leads to	"Increased, Inhibitory postsynaptic potential"
1048	"Increased, Inhibitory postsynaptic potential"	leads to	"Inhibition, Motor neuron activity"
1049	"Inhibition, Motor neuron activity"	leads to	"Induction, Somatic muscle paralysis"
1050	"Induction, Somatic muscle paralysis"	leads to	"Increased, Mortality"
1051	"Activation, ionotropic GABA Receptor chloride channel"	leads to	"Increased, Chloride conductance"
1052	"Increased, Chloride conductance"	leads to	"Increased, Neuronal synaptic inhibition"
1053	"Increased, Neuronal synaptic inhibition"	leads to	"Increased, Inhibitory postsynaptic potential"
1054	"Increased, Inhibitory postsynaptic potential"	leads to	"Induction, Somatic muscle paralysis"
1055	"Induction, Somatic muscle paralysis"	leads to	"Inhibition, Feeding"
1056	"Inhibition, Feeding"	leads to	"Increased, Mortality"
1057	"Activation, Glutamate-gated chloride channels"	leads to	"Increased, Chloride conductance"
1058	"Increased, Inhibitory postsynaptic potential"	leads to	"Induction, pharyngeal muscle paralysis"
1059	"Induction, pharyngeal muscle paralysis"	leads to	"Inhibition, Feeding"
1060	"Induction, Upregulation of glucuronyltransferase activity"	leads to	"Increase, Biliary excretion TH glucuronide"
1061	"Antagonism, Histamine Receptor (H2)"	leads to	"Decrease, histaminergic neuron excitation"
1062	"Formation, The binding of FK506 with FKBP12"	leads to	"Binding, Formation, Binding of calcineurin with FK506-FKBP complexes"
1063	"Increased, induction of UDPGT's in liver"	leads to	"Increased, T4/T3 catabolism"
1064	"Increased, T4/T3 catabolism"	leads to	"Decreased, serum T4/T3"
1065	"Decreased, serum T4/T3"	leads to	"Increased, Thyroid-stimulating hormone (TSH)"
1066	"Increased, Thyroid-stimulating hormone (TSH)"	leads to	"Increased, Hypertrophy and proliferation (follicular cell)"
1067	"Increased, Hypertrophy and proliferation (follicular cell)"	leads to	"Increased, Hyperplasia (follicular cells)"
1068	"Increased, Hyperplasia (follicular cells)"	leads to	"Increased Apoptosis, Adenomas/carcinomas (follicular cell)"
1069	"N/A, Neurodegeneration"	leads to	"Impairment, Learning and memory"
1070	"Inhibition, UROD"	leads to	"Accumulation, Highly carboxylated porphyrins"
1071	"Activation of specific nuclear receptors, PPAR-gamma activation"	leads to	"Increased, adipogenesis"
1072	"Activation of specific nuclear receptors, PPAR-gamma activation"	leads to	"Increased, secretion of local growth factors"
1073	"Increased, adipogenesis"	leads to	"Increased, secretion of local growth factors"
1074	"Increased, secretion of local growth factors"	leads to	"Increased, proliferation of mesenchymal cells"
1075	"Increased, secretion of local growth factors"	leads to	"Increased, IGF-1 (mouse)"
1076	"Increased, proliferation of mesenchymal cells"	leads to	"Increased, Firbrosarcoma"
1077	"Increased, proliferation of mesenchymal cells"	leads to	"Increased, liposarcoma"
1078	"Increased, proliferation of mesenchymal cells"	leads to	"Increased, hemagiosarcoma"
1079	"Activation, beta-2 adrenergic receptor"	leads to	"Increased activity, beta-2 adrenergic receptor"
1080	"Increased activity, beta-2 adrenergic receptor"	leads to	"relaxation, smooth muscle"
1081	"relaxation, smooth muscle"	leads to	"Proliferation/Clonal Expansion, smooth muscle"
1082	"Proliferation/Clonal Expansion, smooth muscle"	leads to	"Hypertrophy/hyperplasia, smooth muscle"
1083	"Hypertrophy/hyperplasia, smooth muscle"	leads to	"Promotion, mesovarian leiomyomas"
1084	"Decreased, Ovarian E2"	leads to	"Increased, secretion of GnRH from hypothalamus"
1085	"Decreased, Ovarian E2"	leads to	"Decrease, E2 blood concentrations at hypothalamus"
1086	"Suppression, Estrogen receptor (ER) activity"	leads to	"Decrease, E2 blood concentrations at hypothalamus"
1087	"Decrease, E2 blood concentrations at hypothalamus"	leads to	"Increased, secretion of GnRH from hypothalamus"
1088	"Increased, secretion of GnRH from hypothalamus"	leads to	"Increased, secrection of FSH from anterior pituitary"
1089	"Increased, secretion of GnRH from hypothalamus"	leads to	"Increased, secretion of LH from anterior pituitary"
1090	"Increased, secrection of FSH from anterior pituitary"	leads to	"Hyperplasia, ovarian stromal cells"
1091	"Increased, secrection of FSH from anterior pituitary"	leads to	"Hyperplasia, ovarian epithelium"
1092	"Increased, secretion of LH from anterior pituitary"	leads to	"Hyperplasia, ovarian stromal cells"
1093	"Hyperplasia, ovarian epithelium"	leads to	"Promotion, ovarian adenomas"
1094	"Hyperplasia, ovarian stromal cells"	leads to	"Promotion, ovarian granular cell tumors"
1095	"Increased, PPAR-alpha activation"	leads to	"Decreased, bile flow"
1096	"Increased, PPAR-alpha activation"	leads to	"Increased, cholestasis"
1097	"Increased, PPAR-alpha activation"	leads to	"Alteration, lipid metabolism"
1098	"prolonged, elevation of serun CCK"	leads to	"Increased, Cellular proliferation / hyperplasia of acinar cells"
1099	"Increased, Cellular proliferation / hyperplasia of acinar cells"	leads to	"Increased, Pancreatic acinar tumors"
1100	"Increased, cholestasis"	leads to	"prolonged, elevation of serun CCK"
1101	"Decreased, bile flow"	leads to	"Increased, cholestasis"
1102	"prepubertal increase, Estrogen receptor (ER) activity"	leads to	"Activation, estrogen receptor alpha"
1103	"Activation, estrogen receptor alpha"	leads to	"Promotion, SIX-1 postive basal-type progenitor cells"
1104	"Promotion, SIX-1 postive basal-type progenitor cells"	leads to	"Proliferation/Clonal Expansion, aberrant basal cells"
1105	"Proliferation/Clonal Expansion, aberrant basal cells"	leads to	"squamous metaplasia, aberrant basal cells"
1106	"squamous metaplasia, aberrant basal cells"	leads to	"Increased, Hyperplasia (glandular epithelial cells of endometrium)"
1107	"Increased, Hyperplasia (glandular epithelial cells of endometrium)"	leads to	"Increased, adenosquamous carcinomas of endometrium"
1108	"Decreased, GnRH pulsatility/release in hypothalamus"	leads to	"Decreased, LH Surge from anterior pituitary"
1109	"Decreased, LH Surge from anterior pituitary"	leads to	"interruption, Ovulation"
1110	"Decreased, LH Surge from anterior pituitary"	leads to	"prolonged, estrus"
1111	"prolonged, estrus"	leads to	"Increased, circulating estrogen levels"
1112	"prolonged, estrus"	leads to	"Increased, prolactin exposure"
1113	"Increased, circulating estrogen levels"	leads to	"Hyperplasia, Mammary gland"
1114	"Increased, prolactin exposure"	leads to	"Hyperplasia, Mammary gland"
1115	"Hyperplasia, Mammary gland"	leads to	"Increased, latency period"
1116	"Hyperplasia, Mammary gland"	leads to	"Increased, Adenomas/carcinomas (mammary)"
1117	"Increased, latency period"	leads to	"Increased, Adenomas/carcinomas (mammary)"
1118	"interruption, Ovulation"	leads to	"Increased, circulating estrogen levels"
1119	"Increased, circulating estrogen levels"	leads to	"Increased, lactotroph hyperplasia and hypertrophy"
1120	"Increased, lactotroph hyperplasia and hypertrophy"	leads to	"Increased, adenomas (pituitary)"
1121	"Decreased, Dopaminergic activity"	leads to	"Increased, prolactin secretion"
1122	"Increased, prolactin secretion"	leads to	"Increased, hyperplasia (mammary gland)"
1123	"Increased, hyperplasia (mammary gland)"	leads to	"Increased, latency period"
1124	"Increased, hyperplasia (mammary gland)"	leads to	"Increased, Adenomas/carcinomas (mammary)"
1125	"persistent, cytotoxicity (pleura or peritoneum)"	leads to	"Increased, inflammation"
1126	"persistent, cytotoxicity (pleura or peritoneum)"	leads to	"Increased, Oxidative Stress"
1127	"Increased, inflammation"	leads to	"Increased, secretion of local growth factors"
1128	"Increased, Oxidative Stress"	leads to	"Increased, secretion of local growth factors"
1129	"Increased, secretion of local growth factors"	leads to	"Increased, Cell Proliferation (mesothelium)"
1130	"Increased, Cell Proliferation (mesothelium)"	leads to	"Increased, mesotheliomas"
1131	"Inhibition, organic anion transporter 1 (OAT1)"	leads to	"Increased, blood uric acid concentration"
1132	"Increased, blood uric acid concentration"	leads to	"Occurrence, tophi (urate) deposition"
1133	"Occurrence, tophi (urate) deposition"	leads to	"Occurrence, renal proximal tubular necrosis"
1134	"Occurrence, renal proximal tubular necrosis"	leads to	"Increased, blood potassium concentration"
1135	"Increased, blood potassium concentration"	leads to	"Occurrence, cardiac arrthymia"
1136	"Occurrence, cardiac arrthymia"	leads to	"Increased, Mortality"
1137	"Inhibition, Cyclooxygenase 1 activity"	leads to	"Decreased, Prostaglandin F2alpha concentration, plasma"
1138	"Decreased, Prostaglandin F2alpha concentration, plasma"	leads to	"Occurrence, renal ischemia"
1139	"Occurrence, renal ischemia"	leads to	"Occurrence, renal proximal tubular necrosis"
1140	"Increased, blood potassium concentration"	leads to	"Occurrence, cardiac arrhythmia"
1141	"Occurrence, cardiac arrhythmia"	leads to	"Increased, Mortality"
1142	"Decreased, Thyroxine (T4) in tissues"	leads to	"Altered, Amphibian metamorphosis"
1143	"Thyroxine (T4) in serum, Decreased"	leads to	"Decreased, Thyroxine (T4) in tissues"
1144	"Abnormal, Foraging activity and behavior"	leads to	"Weakened, Colony"
1145	"Weakened, Colony"	leads to	"Death/Failure, Colony"
1146	"Activation, Nicotinic acetylcholine receptor"	leads to	"Impairment, Learning and memory"
1147	"Activation, Nicotinic acetylcholine receptor"	leads to	"Abnormal, Foraging activity and behavior"
1148	"Abnormal, Foraging activity and behavior"	leads to	"Abnormal, Roll change within caste"
1149	"Abnormal, Roll change within caste"	leads to	"Weakened, Colony"
1150	"Abnormal, Foraging activity and behavior"	leads to	"Abnormal, Role change within caste"
1151	"Abnormal, Role change within caste"	leads to	"Weakened, Colony"
1152	"N/A, Mitochondrial dysfunction 1"	leads to	"impaired, Hive thermoregulation"
1153	"impaired, Hive thermoregulation"	leads to	"Weakened, Colony"
1154	"N/A, Mitochondrial dysfunction 1"	leads to	"Weakened, Colony"
1155	"Increased, Deformed Wing Virus levels"	leads to	"Weakened, Colony"
1156	"Occurrence, renal proximal tubular necrosis"	leads to	"Increased, blood uric acid concentration"
1157	"Increased, Energetic demands and therefore metabolic stress"	leads to	"Abnormal, Foraging activity and behavior"
1158	"Increased, blood uric acid concentration"	leads to	"Increased, Oxidative Stress"
1159	"Occurrence, renal ischemia"	leads to	"Increased, Oxidative Stress"
1160	"Increased, Oxidative Stress"	leads to	"Occurrence, renal proximal tubular necrosis"
1161	"Unknown, MIE"	leads to	"Increased, Reactive oxygen species"
1162	"Increased, Reactive oxygen species"	leads to	"Increased, Oxidative Stress"
1163	"Decreased, Thyroxine (T4) in tissues"	leads to	"Decreased, Triiodothyronine (T3) in tissues"
1164	"Decreased, Triiodothyronine (T3) in tissues"	leads to	"Altered, Amphibian metamorphosis"
1165	"Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo"	leads to	"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"
1166	"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"	leads to	"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur"
1167	"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle"	leads to	"Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo"
1168	"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur"	leads to	"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"
1169	"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"	leads to	"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis"
1170	"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis"	leads to	"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"
1171	"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"	leads to	"Impaired recruitment , Population trajectory"
1172	"Increased, serotonin (5-HT) 1"	leads to	"Increased, valve movement"
1173	"Increased, valve movement"	leads to	"Depletion, energy reserves"
1174	"Increased, valve movement"	leads to	"Increased, water retention in foot"
1175	"Increased, water retention in foot"	leads to	"Increased, foot detachment"
1176	"Increased, foot detachment"	leads to	"Depletion, energy reserves"
1177	"Increased, locomotion"	leads to	"Depletion, energy reserves"
1178	"Increase, cilia movement"	leads to	"premature, spawning 1"
1179	"premature, spawning 1"	leads to	"Decreased, Reproductive Success"
1180	"Decreased, Reproductive Success"	leads to	"Decline, Population"
1181	"Depletion, energy reserves"	leads to	"Delayed, Sexual maturity"
1182	"Delayed, Sexual maturity"	leads to	"Decreased, Reproductive Success"
1183	"Increased, foot detachment"	leads to	"Increase, predation"
1184	"Increase, predation"	leads to	"Decline, Population"
1185	"Depletion, energy reserves"	leads to	"Increase, predation"
1186	"Increased, serotonin (5-HT) 1"	leads to	"Decreased, gametogenesis"
1187	"Increase, cilia movement"	leads to	"premature, Spawning"
1188	"Decreased, gametogenesis"	leads to	"Decreased, Reproductive Success"
1189	"Increased, serotonin (5-HT) 1"	leads to	"Increased, locomotion"
1190	"Induction, Incomplete ecdysis"	leads to	"Increased, Mortality"
1191	"Increased, Mortality"	leads to	"Decreased, Population size"
1192	"Increased, serotonin (5-HT) 1"	leads to	"increased or inappropriate, mantel display"
1193	"increased or inappropriate, mantel display"	leads to	"Decreased, Reproductive Success"
1194	"Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p"	leads to	"Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei"
1195	"Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei"	leads to	"Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp"
1196	"Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp"	leads to	"Osteoporosis and vascular calcification, Bone deterioration"
1197	"Inhibition, Iodotyrosine deiodinase (IYD)"	leads to	"Decreased, Thyroidal iodide uptake"
1198	"Inhibition, Deiodinase 1"	leads to	"Decreased, Triiodothyronine (T3) in tissues"
1199	"Inhibition, Deiodinase 2"	leads to	"Decreased, Triiodothyronine (T3) in tissues"
1200	"Inhibition, Deiodinase 3"	leads to	"Increased, Triiodothyronine (T3) in tissues"
1201	"Increased, Triiodothyronine (T3) in tissues"	leads to	"Altered, Amphibian metamorphosis"
1202	"Inhibition, Pendrin"	leads to	"Thyroid hormone synthesis, Decreased"
1203	"Inhibition, Dual oxidase"	leads to	"Thyroid hormone synthesis, Decreased"
1204	"Activation, Hepatic nuclear receptor(s)"	leads to	"Increased, Hepatic thyroid hormone uptake/transport"
1205	"Activation, Hepatic nuclear receptor(s)"	leads to	"Induction, Upregulation of glucuronyltransferase activity"
1206	"Increased, Hepatic thyroid hormone uptake/transport"	leads to	"Increase, Biliary excretion TH glucuronide"
1207	"Increased, serotonin (5-HT)"	leads to	"Increased, mantel display"
1208	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	"Increased, cilia movement"
1209	"Increased, serotonin (5-HT)"	leads to	"Increased, cilia movement"
1210	"Increased, cilia movement"	leads to	"premature, Spawning"
1211	"premature, Spawning"	leads to	"Increased, Population"
1212	"Increased, serotonin (5-HT)"	leads to	"Increased, oocyte maturation"
1213	"Increased, oocyte maturation"	leads to	"Increased, Reproductive Success"
1214	"Increased, mantel display"	leads to	"Increased, Reproductive Success"
1215	"Increased, Reproductive Success"	leads to	"Increased, Population"
1216	"Increased, valve movement"	leads to	"Increased, water pumping"
1217	"Increase, cilia movement"	leads to	"Increased, water pumping"
1218	"Increase, cilia movement"	leads to	"Depletion, energy reserves"
1219	"increased or inappropriate, mantel display"	leads to	"Depletion, energy reserves"
1220	"increased or inappropriate, mantel display"	leads to	"induced, parturition"
1221	"induced, parturition"	leads to	"Decreased, Reproductive Success"
1222	"premature, Spawning"	leads to	"Decreased, Reproductive Success"
1223	"Increased, water retention in foot"	leads to	"Increased, valve movement"
1224	"Increased, water pumping"	leads to	"Increased, water retention in foot"
1225	"Increased, water pumping"	leads to	"premature, Spawning"
1226	"Increased, water pumping"	leads to	"induced, parturition"
1227	"Increased, valve movement"	leads to	"Increase, predation"
1228	"Increased, muscular waves in foot"	leads to	"Depletion, energy reserves"
1229	"Activation, PPAR?"	leads to	"modulation, Genes/proteins that regulate hepatocyte fate"
1230	"modulation, Genes/proteins that regulate hepatocyte fate"	leads to	"Increase, Mitogenic cell proliferation (hepatocytes)"
1231	"modulation, Genes/proteins that regulate hepatocyte fate"	leads to	"Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci"
1232	"Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci"	leads to	"Increase, Adenomas/carcinomas (hepatocellular)"
1233	"Activation, PPAR?"	leads to	"Increase, Genes involved in fatty acid oxidation"
1234	"Increase, Genes involved in fatty acid oxidation"	leads to	"Increase, Oxidative Stress"
1235	"Activation, NADPH Oxidase"	leads to	"Increase, Oxidative Stress"
1236	"Activation, PPAR?"	leads to	"Activation, NADPH Oxidase"
1237	"Increase, Oxidative Stress"	leads to	"Increase activation, Nuclear factor kappa B (NF-kB)"
1238	"Increase activation, Nuclear factor kappa B (NF-kB)"	leads to	"modulation, Genes/proteins that regulate hepatocyte fate"
1239	"Increase, Mitogenic cell proliferation (hepatocytes)"	leads to	"Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci"
1240	"Increase, Genes involved in fatty acid oxidation"	leads to	"Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids"
1241	"Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids"	leads to	"Increase, Oxidative Stress"
1242	"Inhibition, sodium channel"	leads to	"Decreased, sodium conductance 2"
1243	"Decreased, sodium conductance 2"	leads to	"Decreased, Ionotropic GABA receptor chloride channel conductance"
1244	"Decreased, sodium conductance 2"	leads to	"Decreased, GABA release"
1245	"Decreased, GABA release"	leads to	"Decreased, Chloride conductance"
1246	"Activation, Estrogen receptor"	leads to	"Increased, ER binding to DNA (classical pathway)"
1247	"Increase, Cell Proliferation (Epithelial Cells)"	leads to	"Increased, Ductal Hyperplasia"
1248	"Decreased, Apoptosis (Epithelial Cells)"	leads to	"Increased, Ductal Hyperplasia"
1249	"Activation, Estrogen receptor"	leads to	"Increased, ER binding to T.F. to DNA (non-classical pathway)"
1250	"Increased, ER binding to DNA (classical pathway)"	leads to	"Increase, Cell Proliferation (Epithelial Cells)"
1251	"Increased, ER binding to T.F. to DNA (non-classical pathway)"	leads to	"Increase, Cell Proliferation (Epithelial Cells)"
1252	"Increased, Ductal Hyperplasia"	leads to	"N/A, Breast Cancer"
1253	"Formation, Binding of FK506 to FKBP12"	leads to	"Binding, Formation, Binding of calcineurin with FK506-FKBP complexes"
1254	"Binding, Formation, Binding of calcineurin with FK506-FKBP complexes"	leads to	"Activation, Hampered NFAT activation and following nuclear localization"
1255	"Activation, Hampered NFAT activation and following nuclear localization"	leads to	"Inhibition, Interference of NFAT complex formation at the site of nuclear cytokine promoter"
1256	"Suppression, Suppression of cytokine production in the presence of T-cell activation"	leads to	"Suppression, Suppression of production of cytotoxic T-cells"
1257	"Suppression, Suppression of cytokine production in the presence of T-cell activation"	leads to	"Suppression, Suppression of T-cell dependent antibody production"
1258	"Suppression, Suppression of production of cytotoxic T-cells"	leads to	"Suppression, Suppression of transplant rejection"
1259	"Suppression, Suppression of T-cell dependent antibody production"	leads to	"Increase, Increased susceptibility to infection"
1260	"Suppression, Suppression of production of cytotoxic T-cells"	leads to	"Increase, Increased susceptibility to infection"
1261	"Activation, Juvenile hormone receptor"	leads to	"Induction, Doublesex1 gene"
1262	"Induction, Doublesex1 gene"	leads to	"Induction, Male reproductive tract"
1263	"Induction, Male reproductive tract"	leads to	"Increased, Male offspring"
1264	"Increased, Male offspring"	leads to	"Decline, Population"
1265	"Decline, Population"	leads to	"Alteration, Food-web structures"
1266	"Increased, Proliferation (Endothelial cells)"	leads to	"Increased, Angiogenesis"
1267	"Increased, Migration (Endothelial Cells)"	leads to	"Increased, Angiogenesis"
1268	"Activation, Constitutive androstane receptor"	leads to	"Altered gene expression specific to CAR activation, Hepatocytes"
1269	"Altered gene expression specific to CAR activation, Hepatocytes"	leads to	"Increase, Mitogenic cell proliferation (hepatocytes)"
1271	"TRPA1 activation, TRPA1 Receptor"	leads to	"Opening of calcium channel, Calcium influx"
1272	"Opening of calcium channel, Calcium influx"	leads to	"Sensory airway irritation, Excitation of trigeminal nerves"
1273	"Sensory airway irritation, Excitation of trigeminal nerves"	leads to	"Cough, Dyspnea, Sneezing, Acute respiratory effect"
1274	"Opening of calcium channel, Calcium influx"	leads to	"Excitation, Neuron nerve ending excitation"
1275	"Excitation, Neuron nerve ending excitation"	leads to	"Cough, Dyspnea, Sneezing, Acute respiratory effect"
1276	"Excitation, Neuron nerve ending excitation"	leads to	"Airway Hyper-responsiveness,Cough, Dyspnea, Trigeminal and/or vagal nerve excitation"
1277	"Non-neuronal production of TNF, Epithelial irritation"	leads to	"Leukocyte infiltration, Tissue irritation/inflammation"
1278	"Leukocyte infiltration, Tissue irritation/inflammation"	leads to	"Chronic Cough, Respiratory irritability"
1279	"SP (Substance P) release, Local increase of SP"	leads to	"Non-neuronal production of TNF, Epithelial irritation"
1280	"Opening of calcium channel, Calcium influx"	leads to	"SP (Substance P) release, Local increase of SP"
1281	"TRPV1 activation, TRPV1"	leads to	"Opening of calcium channel, Calcium influx"
1282	"Oxidization of biomolecules, Lipid bilayer and cellular proteins"	leads to	"TRPA1 activation, TRPA1 Receptor"
1283	"Production of nerve growth factor , Epithelial irritation"	leads to	"SP (Substance P) release, Local increase of SP"
1284	"TRPA1 activation, TRPA1 Receptor"	leads to	"Non-neuronal production of IL-8/CXCL1, Epithelial irritation"
1285	"Oxidization of biomolecules, Lipid bilayer and cellular proteins"	leads to	"Generation of novel epitopes , Antigen presentation"
1286	"Oxidization of biomolecules, Lipid bilayer and cellular proteins"	leads to	"Production of nerve growth factor , Epithelial irritation"
1287	"Non-neuronal production of IL-8/CXCL1, Epithelial irritation"	leads to	"Opening of calcium channel, Calcium influx"
1288	"Non-neuronal production of TNF, Epithelial irritation"	leads to	"Opening of calcium channel, Calcium influx"
1289	"Generation of novel epitopes , Antigen presentation"	leads to	"Sensitization, Immune system"
1290	"Leukocyte infiltration, Tissue irritation/inflammation"	leads to	"Sensitization, Immune system"
1291	"Lipid membranes, proteins, DNA, Oxidation of biomolecules"	leads to	"Generation of novel epitopes , Antigen presentation"
1292	"Lipid membranes, proteins, DNA, Oxidation of biomolecules"	leads to	"TRPA1 activation, TRPA1 Receptor"
1293	"Lipid membranes, proteins, DNA, Oxidation of biomolecules"	leads to	"Production of nerve growth factor , Epithelial irritation"
1294	"Activation, Estrogen receptor"	leads to	"Increased, Non-genomic signaling"
1295	"Increased, Non-genomic signaling"	leads to	"Increased, ER binding to T.F. to DNA (non-classical pathway)"
1296	"Increased, ER binding to DNA (classical pathway)"	leads to	"Altered, Gene Expression"
1297	"Increased, ER binding to T.F. to DNA (non-classical pathway)"	leads to	"Altered, Gene Expression"
1298	"Altered, Gene Expression"	leads to	"Altered, Protein Production"
1299	"Altered, Protein Production"	leads to	"Increased, Oxidative Stress"
1300	"Increased, Oxidative Stress"	leads to	"Increased, DNA Damage"
1301	"Increased, DNA Damage"	leads to	"Altered, Gene Expression"
1302	"Increased, Non-genomic signaling"	leads to	"Altered, Gene Expression"
1303	"Altered, Protein Production"	leads to	"Increased, Proliferation (Endothelial cells)"
1304	"Altered, Protein Production"	leads to	"Decreased, Apoptosis (Epithelial Cells)"
1305	"Altered, Protein Production"	leads to	"Increased, Motility"
1306	"Increased, Motility"	leads to	"Increased, Invasion"
1307	"Activation, Estrogen receptor"	leads to	"Increased, Second Messenger Production"
1308	"Increased, Second Messenger Production"	leads to	"Increased, Non-genomic signaling"
1309	"Desensitization, Nicotinic acetylcholine receptor"	leads to	"Altered, Ca2+-calmodulin activated signal transduction"
1310	"Altered, Ca2+-calmodulin activated signal transduction"	leads to	"Impairment, Learning and memory"
1311	"N/A, Mitochondrial dysfunction 1"	leads to	"Altered, Ca2+-calmodulin activated signal transduction"
1312	"Increase, Hyperplasia of goblet cells"	leads to	"Increase, Mucin production"
1313	"Increase, Metaplasia of goblet cells"	leads to	"Increase, Mucin production"
1314	"Chronic, Mucus hypersecretion"	leads to	"Decrease, Lung function"
1315	"Increase, Mucin production"	leads to	"Chronic, Mucus hypersecretion"
1316	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	"Increased, muscular waves in foot"
1317	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	"Increased, valve movement"
1318	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	"Increase, cilia movement"
1319	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	increased mantel display
1320	"Increased, valve movement"	leads to	induced spawning
1321	"Increase, cilia movement"	leads to	induced spawning
1322	increased mantel display	leads to	Induced parturition
1323	Induced parturition	leads to	"Decreased, Reproductive Success"
1324	induced spawning	leads to	"Decreased, Reproductive Success"
1325	induced spawning	leads to	"Increased, Reproductive Success"
1326	Induced parturition	leads to	"Increased, Reproductive Success"
1327	"Increased, serotonin (5-HT)"	leads to	"Increased, valve movement"
1328	"Increased, oocyte maturation"	leads to	induced spawning
1329	"Increased, cilia movement"	leads to	induced spawning
1330	In utero exposure to DNA topoisomerase II “poisons”	leads to	MLL translocation
1331	MLL translocation	leads to	IFL
1332	"Increased, serotonin (5-HT)"	leads to	"Increased, muscular waves in foot"
1333	"Increased, serotonin (5-HT)"	leads to	"Increase, cilia movement"
1334	"Increased, valve movement"	leads to	Induced parturition
1335	"Increase, cilia movement"	leads to	Induced parturition
1336	"Increased, serotonin (5-HT)"	leads to	increased mantel display
1337	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	"Increased, oocyte maturation"
1338	Decompartmentalization	leads to	Mitochondrial impairment
1339	Direct mitochondrial inhibition	leads to	Mitochondrial impairment
1340	narcosis	leads to	Mitochondrial impairment
1341	Mitochondrial impairment	leads to	Apoptosis
1342	Mitochondrial impairment	leads to	Necrosis
1343	"Activation, EcR"	leads to	"Induction, E75b gene"
1344	"Induction, E75b gene"	leads to	"Suppression, Ftz-f1 gene"
1345	"Suppression, Ftz-f1 gene"	leads to	"Reduction, Release of circulating ETH"
1346	"Reduction, Release of circulating ETH"	leads to	"Reduction, Release of circulating CCAP"
1347	"Reduction, Release of circulating CCAP"	leads to	"Reduction, Ecdysis motoneuron bursts"
1348	"Reduction, Ecdysis motoneuron bursts"	leads to	"Reduction, Excitatory postsynaptic potential"
1349	"Reduction, Excitatory postsynaptic potential"	leads to	"Reduction, Abdominal muscle contraction"
1350	"dimerization, AHR/ARNT"	leads to	"Increase, COX-2 expression"
1351	"Increase, COX-2 expression"	leads to	"Altered, Cardiovascular development/function"
1352	"Altered, Cardiovascular development/function"	leads to	"Increase, Mortality"
1353	Inactivation of PPAR?	leads to	Activation of TGF-? signaling
1354	Activation of TGF-? signaling	leads to	Differentiation of Myofibroblast
1355	Activation of TGF-? signaling	leads to	Expression of Collagen
1356	Differentiation of Myofibroblast	leads to	Production of ?-smooth muscle actin
1357	Expression of Collagen	leads to	Collagen Deposition
1358	Production of ?-smooth muscle actin	leads to	Lung fibrosis
1359	Collagen Deposition	leads to	Lung fibrosis
1360	"Activation, NADPH Oxidase"	leads to	ROS formation
1361	ROS formation	leads to	"Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"
1362	"Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"	leads to	"Increased, DNA Damage-Repair"
1363	"Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"	leads to	"Damaging, Mitochondria"
1364	"Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"	leads to	"Activation, HIF-1"
1365	"Activation, HIF-1"	leads to	Apoptosis
1366	"Increased, DNA Damage-Repair"	leads to	Apoptosis
1367	"Damaging, Mitochondria"	leads to	Apoptosis
1368	Apoptosis	leads to	Reproductive failure
1369	"Activation, JAK/STAT pathway"	leads to	"Activation, TGF-beta pathway"
1370	"Activation, TGF-beta pathway"	leads to	Reproductive failure
1371	"Up Regulation, SREBF2"	leads to	"Up Regulation, Unsaturated fatty acid"
1372	"Up Regulation, Unsaturated fatty acid"	leads to	Perturbation of cholesterol
1373	"Down Regulation, GSS and GSTs gene"	leads to	Glutathione synthesis
1374	Glutathione synthesis	leads to	"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"
1375	"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"	leads to	Perturbation of cholesterol
1376	"Down Regulation, GSS and GSTs gene"	leads to	Glutathione homeostasis
1377	Perturbation of cholesterol	leads to	Hepatotoxicity
1378	Glutathione homeostasis	leads to	Hepatotoxicity
1379	"Increase, Oxidative Stress"	leads to	"Activation, JNK"
1380	"Activation, JNK"	leads to	"Activation, FOXO"
1381	"Activation, FOXO"	leads to	"Inhibition, Wnt pathway"
1382	"Inhibition, Wnt pathway"	leads to	Defect of Embryogenesis
1383	Defect of Embryogenesis	leads to	Reproductive failure
1384	"Agonism, Androgen receptor"	leads to	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
1385	"Agonism, Androgen receptor"	leads to	"Reduction, Vitellogenin synthesis in liver"
1386	"Reduction, Plasma 17beta-estradiol concentrations"	leads to	"Reduction, Plasma vitellogenin concentrations"
1387	"Thyroxine (T4) in serum, Decreased"	leads to	"Hippocampal gene expression, Altered"
1388	"Thyroxine (T4) in serum, Decreased"	leads to	"Hippocampal anatomy, Altered"
1389	"Thyroxine (T4) in serum, Decreased"	leads to	"Hippocampal Physiology, Altered"
